[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 134
1. Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R, Abbruzzese JL: Metastatic patterns in adenocarcinoma. Cancer; 2006 Apr 1;106(7):1624-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic patterns in adenocarcinoma.
  • BACKGROUND: Unique metastatic patterns cited in the literature often arise from anecdotal clinical observations and autopsy reports.
  • The authors analyzed clinical data from a large number of patients with histologically confirmed, distant-stage adenocarcinoma to evaluate metastatic patterns.
  • METHODS: Tumor registry data were collected between 1994-1996 on 11 primary tumor sites and 15 metastatic sites from 4399 patients.
  • The primary and metastatic sites were cross-tabulated in various ways to identify patterns, and the authors developed algorithms by using multinomial logistic regression analysis to predict the locations of primary tumors based on metastatic patterns.
  • RESULTS: Three primary tumors had single, dominant metastatic sites: ovary to abdominal cavity (91%), prostate to bone (90%), and pancreas to liver (85%).
  • The liver was the dominant metastatic site for gastrointestinal (GI) primary tumors (71% of patients), whereas bone and lung metastases were noted most frequently in non-GI primary tumors (43% and 29%, respectively).
  • In a study of combinations of liver, abdominal cavity, and bone metastases, 86% of prostate primary tumors had only bone metastases, 80% of ovarian primary tumors had only abdominal cavity metastases, and 74% of pancreas primary tumors had only liver metastases.
  • A single organ was the dominant source of metastases in 7 sites: axillary lymph node from the breast (97%), intestinal lymph node from the colon (84%), thoracic lymph node from the lung (66%), brain from the lung (64%), mediastinal lymph node from the lung (62%), supraclavicular lymph node from the breast (51%), and adrenal gland from the lung (51%).
  • [MeSH-major] Adenocarcinoma / secondary. Algorithms. Neoplasm Metastasis. Registries / statistics & numerical data

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16518827.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Shibakuki R, Seto T, Uematsu K, Shimizu K, Seki N, Nakano M, Ishii H, Ohta M, Eguchi K: Pulmonary adenocarcinoma associated with SAPHO syndrome difficult to differentiate from multiple bone metastasis. Intern Med; 2006;45(8):543-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary adenocarcinoma associated with SAPHO syndrome difficult to differentiate from multiple bone metastasis.
  • The patient was a 57-year-old man with a chief complaint of anterior chest pain who was diagnosed with clinical stage IV (c-T2N2M1) non-small-cell lung cancer (adenocarcinoma).
  • Bone scintigraphy showed tracer accumulation in the costal cartilage, sternoclavicular joint, and cervical vertebrae 6-7.
  • Although the bone lesions of SAPHO syndrome were difficult to differentiate from bone metastasis of pulmonary adenocarcinoma, metastatic bone tumors were ruled out by magnetic resonance imaging, computed tomography, and fluorodeoxyglucose positron emission tomography.
  • There have been no previously reported cases of lung cancer with comorbid SAPHO syndrome.
  • We report such a case and discuss the relevant literature, particularly that concerned with the evaluation of bone lesions.
  • [MeSH-major] Acquired Hyperostosis Syndrome / complications. Adenocarcinoma / complications. Adenocarcinoma / secondary. Bone Neoplasms / diagnosis. Bone Neoplasms / secondary. Lung Neoplasms / complications
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - SAPHO syndrome.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16702748.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


3. Sánchez-Jiménez J, Acebal-Blanco F, Arévalo-Arévalo RE, Molina-Martínez M: Metastatic tumours in upper maxillary bone of esophageal adenocarcinoma. A case report. Med Oral Patol Oral Cir Bucal; 2005 May-Jul;10(3):252-7
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic tumours in upper maxillary bone of esophageal adenocarcinoma. A case report.
  • Primary tumours which metastasize to mouth are most commonly: lung, breast and kidney.
  • Here we present a clinical case of a patient diagnosed with esophagus adenocarcinoma which presented metastasis in upper-left maxillary bone.
  • [MeSH-major] Adenocarcinoma / secondary. Esophageal Neoplasms / pathology. Maxillary Neoplasms / secondary. Maxillary Sinus Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15876970.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng; spa
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


Advertisement
4. Nguyen DX, Chiang AC, Zhang XH, Kim JY, Kris MG, Ladanyi M, Gerald WL, Massagué J: WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell; 2009 Jul 10;138(1):51-62
eagle-i research resources. PMID 19576624 (Special Collections) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis.
  • Metastasis from lung adenocarcinoma can occur swiftly to multiple organs within months of diagnosis.
  • The mechanisms that confer this rapid metastatic capacity to lung tumors are unknown.
  • Activation of the canonical WNT/TCF pathway is identified here as a determinant of metastasis to brain and bone during lung adenocarcinoma progression.
  • Gene expression signatures denoting WNT/TCF activation are associated with relapse to multiple organs in primary lung adenocarcinoma.
  • Metastatic subpopulations isolated from independent lymph node-derived lung adenocarcinoma cell lines harbor a hyperactive WNT/TCF pathway.
  • Reduction of TCF activity in these cells attenuates their ability to form brain and bone metastases in mice, independently of effects on tumor growth in the lungs.
  • Thus, a distinct WNT/TCF signaling program through LEF1 and HOXB9 enhances the competence of lung adenocarcinoma cells to colonize the bones and the brain.


5. Yang S, Su J, Cao J, Zhang P, Lu J, Xie W: [Establishment of a Novel Chinese Human Lung Adenocarcinoma Cell Line CPA-Yang1 which Produces Highly Bone Metastases in Immunodeficient Mice.]. Zhongguo Fei Ai Za Zhi; 2009 Jul 20;12(7):753-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Establishment of a Novel Chinese Human Lung Adenocarcinoma Cell Line CPA-Yang1 which Produces Highly Bone Metastases in Immunodeficient Mice.].
  • BACKGROUND: Lung cancer is a common malignancy and is the major determinant of overall cancer mortality worldwidely.
  • Approximately 70% of lung cancer patients will die from metastatic diseases.
  • The aim of this study is to establish a Chinese lung adenocarcinoma cell line with high metastasis potency for exploring the mechanism of occurrence and development in lung cancer.
  • METHODS: The cell came from the pericardial effusion of a fifty-year old male patient with lung adenocarcinoma and the cells in primary culture were obtained successfully.
  • The bone metastasis rate was 90% in the tumor bearing mice by bone scintigraphy and pathology and only pulmonary metastasis 10% at the same time.
  • Quantitative real-time PCR was used to examined and compared SPC-A-1 lung adenocarcinoma, VEGF-C, IL-6, IL-8, genes were overexpressed.
  • CONCLUSIONS: Tne novel strain CPA-Yang1 is an parental cell with characteristics of bone metastasis of Chinese lung adenocarcinoma.
  • It has stable traits, highly metastatic ability and a good experimental model for lung cancer research.

  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20719150.001).
  • [ISSN] 1999-6187
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


6. Tohfe M, Baki SA, Saliba W, Ghandour F, Ashou R, Ghazal G, Bahous J, Chamseddine N: Metastatic prostate adenocarcinoma presenting with pulmonary symptoms: a case report and review of the literature. Cases J; 2008;1(1):316

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic prostate adenocarcinoma presenting with pulmonary symptoms: a case report and review of the literature.
  • INTRODUCTION: Prostate cancer has a high tendency to spread to bone.
  • Pulmonary metastasis and generalized lymphadenopathy commonly develop after pelvic and bone involvement have already occurred.
  • Few patients with prostate cancer present initially with symptomatic metastatic lung lesions and lymphadenopathy without any other concomitant distant dissemination.
  • A chest X-ray was done revealing multiple "cannon ball" infiltrates involving all segments of the lung parenchyma.
  • Despite the absence of any detectable osseous lesions and with the presence of multiple hilar, mediastinal, para-aortic, and pelvic lymphadenopathy, the patient had a complete work-up in search for the primary adenocarcinoma.
  • His prostate specific antigen was 146 ng/ml and a prostatic biopsy done, revealing an acinar prostatic adenocarcinoma.
  • A tru-cut biopsy of a lung lesion under computed tomography guidance showed a metastatic prostatic adenocarcinoma positive for prostate specific antigen stain.
  • CONCLUSION: This case sheds light on an unusual metastatic pattern of prostatic adenocarcinoma.
  • It also emphasizes the importance of including prostate cancer in the differential diagnosis of men with adenocarcinoma of unknown origin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Urol Oncol. 2006 May-Jun;24(3):216-9 [16678051.001]
  • [Cites] Urol Int. 1998 Oct;61(1):17-21 [9792977.001]
  • [Cites] Cancer. 1995 Jun 1;75(11):2706-9 [7743474.001]
  • [Cites] Hum Pathol. 2000 May;31(5):578-83 [10836297.001]
  • [Cites] Cancer. 1984 Dec 15;54(12):3078-84 [6498785.001]
  • [Cites] Cancer. 1990 Apr 15;65(8):1843-6 [2317763.001]
  • [Cites] Mil Med. 2000 Dec;165(12):973-4 [11149072.001]
  • [Cites] Radiology. 1985 Mar;154(3):601-4 [2578678.001]
  • (PMID = 19014682.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2590613
  •  go-up   go-down


7. Tazi N, Le Thi Huong D, Bodaghi B, Rixe O, Lehoang P, Piette JC: [Choroidal metastasis revealing pulmonary adenocarcinoma]. Rev Med Interne; 2006 Sep;27(9):699-701
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Choroidal metastasis revealing pulmonary adenocarcinoma].
  • Lung cancer is the first cause of choroidal metastasis in man.
  • He presented with visual decrease and metamorphopsia that lead to the diagnosis of a metastatic adenocarcinoma of the lung (bone, liver, choroid, nodles).

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16872723.001).
  • [ISSN] 0248-8663
  • [Journal-full-title] La Revue de medecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] FRE
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


8. Mego M, Sycova-Mila Z, Martanovic P, Liskova S, Obertova J, Mardiak J: Inflammatory skin metastasis as a first sign of progression of lung cancer--a case report. Klin Onkol; 2010;23(6):449-51
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory skin metastasis as a first sign of progression of lung cancer--a case report.
  • ICM in lung cancer are extremely rare and often misdiagnosed.
  • PATIENTS AND METHODS: We report on a 55-year-old man with metastatic lung adenocarcinoma and bone metastases in the axial skeleton and left humerus diagnosed in August 2008.
  • A diagnosis of skin infection was made and he was treated by antibiotic therapy without improvement.
  • RESULTS: Skin biopsy revealed skin infiltration by poorly differentiated carcinoma compatible with a primary lung tumour.
  • CONCLUSION: Metastasis of lung carcinoma could be one of the causes of inflammatory skin lesions in cancer patients and these metastases should be considered in cancer patients with persisting cutaneous lesions with signs of inflammation and no response to antibiotic therapy.
  • [MeSH-major] Adenocarcinoma / secondary. Lung Neoplasms / pathology. Skin Neoplasms / secondary
  • [MeSH-minor] Bone Neoplasms / secondary. Humans. Male. Middle Aged. Skin / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21348413.001).
  • [ISSN] 0862-495X
  • [Journal-full-title] Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti
  • [ISO-abbreviation] Klin Onkol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


9. Hill HC: Challenges of utilizing immunostains to facilitate the diagnosis and management of metastatic adenocarcinoma. J Natl Med Assoc; 2008 Dec;100(12):1469-73
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Challenges of utilizing immunostains to facilitate the diagnosis and management of metastatic adenocarcinoma.
  • Treatment is based upon the results of several diagnostic radiographic modalities that may locate the occult primary and determine the extent of metastatic tumor burden.
  • We describe metastatic adenocarcinoma of unknown primary presenting as a pericardial effusion and coincident supraclavicular adenopathy.
  • The patient completed the chemotherapy and had stable metastatic tumor burden with an acceptable quality of life.
  • Two years after initial diagnosis, the patient expired because of disease progression.
  • Although immunohistochemical staining initially suggested metastatic breast carcinoma, her clinical course confirmed a lung primary.
  • [MeSH-major] Adenocarcinoma / secondary. Lung Neoplasms / diagnosis. Lung Neoplasms / pathology. Neoplasms, Unknown Primary / diagnosis
  • [MeSH-minor] Adult. Bone Neoplasms / secondary. Brain Neoplasms / secondary. Bromhexine. Fatal Outcome. Female. Humans. Immunohistochemistry. Pericardial Effusion / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Med Assoc. 2009 May;101(5):478 [19476202.001]
  • (PMID = 19110917.001).
  • [ISSN] 1943-4693
  • [Journal-full-title] Journal of the National Medical Association
  • [ISO-abbreviation] J Natl Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q1J152VB1P / Bromhexine
  •  go-up   go-down


10. Kai N, Ishii H, Morinag R, Sonoda H, Oka H, Amemiya Y, Iwata A, Otani S, Umeki K, Sakashita H, Kadota J: [Pulmonary adenocarcinoma with facial nerve palsy as the first sign of onset due to a metastatic temporal bone tumor]. Nihon Kokyuki Gakkai Zasshi; 2009 Apr;47(4):304-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary adenocarcinoma with facial nerve palsy as the first sign of onset due to a metastatic temporal bone tumor].
  • Brain magnetic resonance imaging showed a mass lesion with a well-enhanced margin in the left temporal bone.
  • A computed tomographic scan of the chest showed a lung mass in the left lower lobe, which was thereafter diagnosed as adenocarcinoma.
  • An immunohistochemical examination of the tissue specimen obtained from the left temporal bone revealed evidence of metastatic adenocarcinoma from the lung.
  • No other metastatic lesions including separate site of bone were seen.
  • This is a very rare case of lung cancer with facial nerve palsy as the first sign of onset due to a metastatic temporal bone tumor.
  • [MeSH-major] Adenocarcinoma / pathology. Facial Paralysis / etiology. Lung Neoplasms / pathology. Skull Neoplasms / secondary. Temporal Bone

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19455960.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


11. Keramidas E, Brotherston M: Extensive metastasis to the hand from undiagnosed adenocarcinoma of the lung. Scand J Plast Reconstr Surg Hand Surg; 2005;39(2):113-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extensive metastasis to the hand from undiagnosed adenocarcinoma of the lung.
  • Metastatic tumours of the hand are uncommon; we present a case of undiagnosed adenocarcinoma of the lung with extensive metastases to the carpal, and to the third, fourth, and fifth metacarpal, bones.
  • Biopsy confirmed the diagnosis and the patient died three months later, no surgical treatment being offered.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019740.001).
  • [ISSN] 0284-4311
  • [Journal-full-title] Scandinavian journal of plastic and reconstructive surgery and hand surgery
  • [ISO-abbreviation] Scand J Plast Reconstr Surg Hand Surg
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


12. Sato T, Soejima K, Nakayama S, Satomi R, Sayama K, Asano K: [A case of fat embolism syndrome associated with pathological femoral fracture caused by metastatic adenocarcinoma of the lung]. Nihon Kokyuki Gakkai Zasshi; 2010 Oct;48(10):765-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of fat embolism syndrome associated with pathological femoral fracture caused by metastatic adenocarcinoma of the lung].
  • A 76-year-old woman with multiple bone metastases from lung adenocarcinoma was admitted due to a pathological femoral fracture.
  • Fat embolism syndrome should be considered as a differential diagnosis if consciousness disturbance and respiratory failure occur in patients with metastatic bone carcinoma and pathological long bone fractures.
  • [MeSH-major] Adenocarcinoma / complications. Embolism, Fat / etiology. Femoral Fractures / etiology. Fractures, Spontaneous / etiology. Lung Neoplasms / complications
  • [MeSH-minor] Aged. Bone Neoplasms / secondary. Female. Humans

  • Genetic Alliance. consumer health - Embolism.
  • MedlinePlus Health Information. consumer health - Leg Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21066866.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


13. Tomita A, Kasaoka T, Inui T, Toyoshima M, Nishiyama H, Saiki H, Iguchi H, Nakajima M: Human breast adenocarcinoma (MDA-231) and human lung squamous cell carcinoma (Hara) do not have the ability to cause bone resorption by themselves during the establishment of bone metastasis. Clin Exp Metastasis; 2008;25(4):437-44
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human breast adenocarcinoma (MDA-231) and human lung squamous cell carcinoma (Hara) do not have the ability to cause bone resorption by themselves during the establishment of bone metastasis.
  • Osteolysis is an important process in the establishment of bone metastasis.
  • In this study, we first established a reproducible in vivo bone metastasis model using two types of tumor cells, human breast adenocarcinoma (MDA-231) and human lung squamous cell carcinoma (Hara cells), and examined in vitro characteristics of the tumor cells.
  • Tumor cells injected into the left heart ventricle of nude mice preferentially metastasized to bone, 6 weeks after the inoculation.
  • Histological observation of the bone metastatic lesion showed that tumor cells invaded the bone marrow, and osteoclasts adjacent to fibroblasts were actively resorbing the bone matrix.
  • In vitro analysis of the tumor cells showed that MDA-231 cells express cathepsin K, matrix metalloproteinase 9 (MMP-9), and membrane type-1 matrix metalloproteinase (MT1-MMP), all of which are believed to play an important role in osteoclastic bone resorption.
  • Taken together, we conclude that MDA-231 and Hara cells, which metastasize to the bone in vivo, do not have enough ability to achieve bone resorption by themselves, but rather achieve it through activation of fibroblast like cells and osteoclasts.
  • [MeSH-major] Adenocarcinoma / pathology. Bone Neoplasms / secondary. Bone Resorption / etiology. Breast Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Lung Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2001 Oct 1;94(1):24-7 [11668474.001]
  • [Cites] Endocrinology. 1999 Oct;140(10):4451-8 [10499498.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):11001-9 [16322249.001]
  • [Cites] Cancer Res. 1996 Sep 1;56(17):4040-3 [8752176.001]
  • [Cites] Bone Miner. 1992 Jun;17(3):347-59 [1623329.001]
  • [Cites] Cancer Res. 1993 Dec 1;53(23):5802-7 [8242639.001]
  • [Cites] Scan Electron Microsc. 1986;(Pt 4):1537-54 [3544196.001]
  • [Cites] J Biol Chem. 1998 Nov 27;273(48):32347-52 [9822715.001]
  • [Cites] J Biol Chem. 1994 Jan 14;269(2):1106-9 [8288568.001]
  • [Cites] J Biol Chem. 1997 Mar 28;272(13):8109-12 [9079619.001]
  • [Cites] J Bone Miner Res. 1998 Jan;13(1):59-66 [9443791.001]
  • [Cites] Life Sci. 2006 Sep 20;79(17):1657-60 [16806280.001]
  • [Cites] Nature. 1994 Jul 7;370(6484):61-5 [8015608.001]
  • [Cites] Cancer Res. 1999 Nov 15;59(22):5849-55 [10582709.001]
  • [Cites] J Cell Sci. 1997 Mar;110 ( Pt 5):589-96 [9092941.001]
  • [Cites] Br J Cancer. 2003 Apr 22;88(8):1318-26 [12698202.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13453-8 [9811821.001]
  • [Cites] Lab Invest. 1995 Mar;72(3):311-22 [7898050.001]
  • [Cites] Biochem Biophys Res Commun. 1992 Jul 31;186(2):911-7 [1379809.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Jan 5;206(1):89-96 [7818555.001]
  • [Cites] Bone. 1997 Feb;20(2):81-6 [9028530.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Apr 29;258(1):173-8 [10222255.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5571-9 [12359770.001]
  • [Cites] Bone. 2003 Jul;33(1):28-37 [12919697.001]
  • [Cites] J Surg Res. 2001 Sep;100(1):18-24 [11516200.001]
  • [Cites] Cancer Res. 1995 Aug 15;55(16):3551-7 [7627963.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jun 25;319(2):690-6 [15178461.001]
  • [Cites] Tissue Cell. 2001 Oct;33(5):478-82 [11949783.001]
  • [Cites] Anat Rec A Discov Mol Cell Evol Biol. 2003 Feb;270(2):152-61 [12524690.001]
  • [Cites] J Biol Chem. 1994 May 27;269(21):15006-9 [8195136.001]
  • [Cites] Endocr Rev. 1999 Jun;20(3):345-57 [10368775.001]
  • [Cites] J Biol Chem. 1996 Jan 26;271(4):2126-32 [8567669.001]
  • [Cites] J Clin Invest. 1996 Oct 1;98(7):1544-9 [8833902.001]
  • [Cites] J Biol Chem. 1996 May 24;271(21):12511-6 [8647859.001]
  • [Cites] J Cell Biol. 2000 Nov 13;151(4):879-89 [11076971.001]
  • [Cites] J Biol Chem. 1995 Jan 13;270(2):801-5 [7822314.001]
  • (PMID = 18301992.001).
  • [ISSN] 0262-0898
  • [Journal-full-title] Clinical & experimental metastasis
  • [ISO-abbreviation] Clin. Exp. Metastasis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Parathyroid Hormone-Related Protein; 0 / RNA, Messenger; EC 3.4.- / Cathepsins; EC 3.4.22.38 / CTSK protein, human; EC 3.4.22.38 / Cathepsin K; EC 3.4.22.38 / Ctsk protein, mouse; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.4.24.80 / Matrix Metalloproteinase 14
  •  go-up   go-down


14. Casal J, Vázquez S, León L, Lázaro M, Fírvida JL, Amenedo M, Alonso G, Santomé L, Afonso FJ: Erlotinib as maintenance therapy after concurrent chemoradiotherapy in patients (p) with stage III non-small cell lung cancer (NSCLC): A Galician Lung Cancer Group phase II study. J Clin Oncol; 2009 May 20;27(15_suppl):7537

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erlotinib as maintenance therapy after concurrent chemoradiotherapy in patients (p) with stage III non-small cell lung cancer (NSCLC): A Galician Lung Cancer Group phase II study.
  • Erlotinib is an EGFR TKI that prolongs survival in p with recurrent and metastatic NSCLC.
  • Main eligibility criteria were: PS 0-2, adequate bone marrow, hepatic and renal function and measurable disease by RECIST criteria.
  • Baseline characteristics: median age 62 years (range 41-76); male 94.6%; caucasian 100%; smokers/never smokers (%) 97.3/2.7; ECOG PS 0/1/2 (%) 18.9/75.7/2.7; adenocarcinoma/squamous cell carcinoma/large cell carcinoma (%) 16.2/75.7/5.4; stage IIIA/IIIB (%) 16.2/83.8.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963306.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. McLean SR, Shousha S, Francis N, Lim A, Eccles S, Nathan M, Brock CS, Palmieri C: Metastatic ductal eccrine adenocarcinoma masquerading as an invasive ductal carcinoma of the male breast. J Cutan Pathol; 2007 Dec;34(12):934-8
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic ductal eccrine adenocarcinoma masquerading as an invasive ductal carcinoma of the male breast.
  • We report the case of a 38-year-old man with metastatic ductal eccrine adenocarcinoma (DEA) of the left breast responding to 5-flourouracil, epirubicin and cyclophosphamide (FEC) chemotherapy.
  • A punch biopsy of the breast lesion resulted in a diagnosis of metastatic invasive ductal carcinoma (IDC) of the breast.
  • Both the morphological and the immunohistochemical characteristics of the tumor were consistent with a revised diagnosis of DEA rather than IDC.
  • In addition, clinical response to FEC by metastatic DEA has not been previously documented, and this therapeutic regimen warrants further investigation.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms, Male / pathology. Carcinoma, Ductal, Breast / pathology. Eccrine Glands / pathology. Sweat Gland Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Bone Density Conservation Agents / therapeutic use. Bone Neoplasms / secondary. Bone Neoplasms / therapy. Cyclophosphamide / therapeutic use. Diphosphonates / therapeutic use. Epirubicin / therapeutic use. Fluorouracil / therapeutic use. Humans. Immunohistochemistry. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Lymphatic Metastasis / pathology. Male. Radiotherapy. Tamoxifen / therapeutic use. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18001417.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Bone Density Conservation Agents; 0 / Diphosphonates; 094ZI81Y45 / Tamoxifen; 114084-78-5 / ibandronic acid; 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil
  •  go-up   go-down


16. Charoentum C: Thai female non-smoker with recurrent lung adenocarcinoma who has dramatic and prolonged response to gefitinib for over one year. J Med Assoc Thai; 2006 Jun;89(6):882-6
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thai female non-smoker with recurrent lung adenocarcinoma who has dramatic and prolonged response to gefitinib for over one year.
  • A 53-year old non-smoking Thai female was diagnosed with metastatic non-small cell lung cancer to bone.
  • The initial biopsy from the bone lesion showed metastatic adenocarcinoma.
  • This result is consistent with previous reports that the clinical characteristics of female, non-smoker and adenocarcinoma histology seem to predict response to gefitinib.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Neoplasm Recurrence, Local / drug therapy. Protein Kinase Inhibitors / therapeutic use. Quinazolines / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16850692.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


17. Chou WC, Huang SF, Yeh KY, Wang HM, Liu MY, Hsieh JJ, Cheung YC, Chang JW: Different responses to gefitinib in lung adenocarcinoma coexpressing mutant- and wild-type epidermal growth factor receptor genes. Jpn J Clin Oncol; 2006 Aug;36(8):523-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different responses to gefitinib in lung adenocarcinoma coexpressing mutant- and wild-type epidermal growth factor receptor genes.
  • Here we report the different treatment responses in a case of lung adenocarcinoma coexpressing mutant-type gene in the primary lung mass and a wild-type gene in the metastatic bone lesions.
  • [MeSH-major] Adenocarcinoma / genetics. Antineoplastic Agents / therapeutic use. Genes, erbB-1 / drug effects. Lung Neoplasms / genetics. Mutation. Protein Kinase Inhibitors / therapeutic use. Quinazolines / therapeutic use. Spinal Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16803841.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


18. Ahmed I, Robinson CM, Patton JT, Cook RE: Metastatic adenocarcinoma after intramedullary fixation of a tibial fracture: A report of two cases. J Bone Joint Surg Br; 2010 Nov;92(11):1592-5
MedlinePlus Health Information. consumer health - Leg Injuries and Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adenocarcinoma after intramedullary fixation of a tibial fracture: A report of two cases.
  • We present two cases of metastatic lung cancer which occurred at the site of a previously united tibial fracture.
  • We are unaware of any previous reports of a metastatic tumour occurring at the site of an orthopaedic implant used to stabilise a non-pathological fracture.
  • These cases demonstrate the similar clinical presentation of infection and malignancy: a diagnosis which should always be considered in such patients.
  • [MeSH-major] Adenocarcinoma / secondary. Bone Neoplasms / secondary. Fracture Fixation, Intramedullary / adverse effects. Tibia. Tibial Fractures / surgery
  • [MeSH-minor] Aged. Female. Fracture Healing. Humans. Lung Neoplasms / diagnosis. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21037359.001).
  • [ISSN] 0301-620X
  • [Journal-full-title] The Journal of bone and joint surgery. British volume
  • [ISO-abbreviation] J Bone Joint Surg Br
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


19. Wu Y, Yao LQ, Cheng J, Tian H: [Diagnostic value of bone marrow biopsy for bone marrow metastatic tumor with unknown primary tumor site]. Nan Fang Yi Ke Da Xue Xue Bao; 2010 May;30(5):1069-71

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnostic value of bone marrow biopsy for bone marrow metastatic tumor with unknown primary tumor site].
  • OBJECTIVE: To explore the diagnostic value of bone marrow biopsy for bone marrow metastatic tumor with unknown primary tumor site.
  • METHODS: Thirty-eight cases of metastatic bone marrow tumors were diagnosed by light microscopy, and the bone marrow samples from these cases with unknown primary tumor sites were examined by immunohistochemistry.
  • RESULTS: In all the cases, the bone marrow was infiltrated by tumor cells between the bone trabecula.
  • Immunohistochemistry identified the primary tumor sites in these cases, including 12 stomach cancers, 10 breast cancers, 8 prostate cancers, 4 lung cancers, 1 dorsal melanoma, 1 left foot melanoma, and 2 nasopharyngeal cancers.
  • CONCLUSION: Proper immunohistochemistry can help determine the primary tumor sites in patients with metastatic bone marrow tumor with unknown primary tumor sites.
  • [MeSH-major] Adenocarcinoma / secondary. Bone Marrow Examination / methods. Bone Marrow Neoplasms / diagnosis. Bone Marrow Neoplasms / secondary. Neoplasms, Unknown Primary / diagnosis
  • [MeSH-minor] Adult. Aged. Biopsy, Needle. Female. Humans. Lung Neoplasms / diagnosis. Lung Neoplasms / pathology. Male. Middle Aged. Stomach Neoplasms / diagnosis. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20501396.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


20. Yang S, Dong Q, Yao M, Shi M, Ye J, Zhao L, Su J, Gu W, Xie W, Wang K, Du Y, Li Y, Huang Y: Establishment of an experimental human lung adenocarcinoma cell line SPC-A-1BM with high bone metastases potency by (99m)Tc-MDP bone scintigraphy. Nucl Med Biol; 2009 Apr;36(3):313-21
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment of an experimental human lung adenocarcinoma cell line SPC-A-1BM with high bone metastases potency by (99m)Tc-MDP bone scintigraphy.
  • BACKGROUND: Bone metastasis is one of the most common clinical phenomena of late stage lung cancer.
  • A major impediment to understanding the pathogenesis of bone metastasis has been the lack of an appropriate animal and cell model.
  • This study aims to establish human lung adenocarcinoma cell line with highly bone metastases potency with (99m)Tc-MDP bone scintigraphy.
  • METHODS: The human lung adenocarcinoma cancer cells SPC-A-1 were injected into the left cardiac ventricle of NIH-Beige-Nude-XID (NIH-BNX) immunodeficient mice.
  • The metastatic lesions of tumor-bearing mice were imaged with (99m)Tc-MDP bone scintigraphy on a Siemens multi-single photon emission computed tomography.
  • The mice with bone metastasis were sacrificed under deep anesthesia, and the lesions were resected.
  • Bone metastatic cancer cells in the resected lesions were subjected for culture and then reinoculated into the NIH-BNX mice through left cardiac ventricle.
  • RESULTS: The bone metastasis sites were successfully revealed by bone scintigraphy.
  • The established bone metastasis cell line SPC-A-1BM had a high potential to metastasize in bone, including mandible, humerus, thoracic vertebra, lumbar, femur, patella, ilium and cartilage rib.
  • Gene expression difference was found between parental and bone-seeking metastasis cell SPC-A-1BM, which indicates SPC-A-1BM has metastatic capacity vs. its parental cells.
  • CONCLUSION: SPC-A-1BM is a bone-seeking metastasis human lung adenocarcinoma cell line.
  • Bone scintigraphy may be used as an accurate, sensitive, noninvasive tool to detect experimental bone metastases in intact live NIH-BNX mice.
  • [MeSH-major] Adenocarcinoma / pathology. Bone Neoplasms / radionuclide imaging. Bone Neoplasms / secondary. Bone and Bones / radionuclide imaging. Lung Neoplasms / pathology. Technetium Tc 99m Medronate

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19324277.001).
  • [ISSN] 1872-9614
  • [Journal-full-title] Nuclear medicine and biology
  • [ISO-abbreviation] Nucl. Med. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] X89XV46R07 / Technetium Tc 99m Medronate
  •  go-up   go-down


21. Langenfeld EM, Bojnowski J, Perone J, Langenfeld J: Expression of bone morphogenetic proteins in human lung carcinomas. Ann Thorac Surg; 2005 Sep;80(3):1028-32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of bone morphogenetic proteins in human lung carcinomas.
  • BACKGROUND: The bone morphogenetic proteins (BMP) are phytogenetically conserved proteins, which are essential for embryonic development.
  • Bone morphogenetic protein-2 (BMP-2) was recently shown to be expressed in a small sample of lung carcinomas.
  • The present study examined which BMP family members are expressed in non-small cell lung carcinomas (NSCLC).
  • Furthermore, the frequency of BMP-2 overexpression and the types of lung carcinomas expressing BMP-2 were determined.
  • Samples included metastatic NSCLC, benign lung tumors, adenocarcinoma, squamous cell carcinoma, bronchioloalveolar, and neuroendocrine carcinomas.
  • Paired normal lung tissues served as the controls.
  • The BMP-2 was expressed in 41 of 42 NSCLC with minimal expression in normal lung tissue; BMP-2 was expressed 17 fold higher than that of normal lung tissue.
  • The BMP-2 was not significantly expressed in benign lung tumors.
  • CONCLUSIONS: Bone morphogenetic protein-2 is the predominant family member expressed in NSCLC.
  • The BMP-2 is overexpressed in the majority of human lung carcinomas independent of cell type.
  • [MeSH-major] Bone Morphogenetic Proteins / metabolism. Lung Neoplasms / genetics. Lung Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Bone Morphogenetic Protein 2. Bone Morphogenetic Protein 4. Bone Morphogenetic Protein 6. Bone Morphogenetic Protein 7. Carcinoma, Neuroendocrine / genetics. Carcinoma, Neuroendocrine / metabolism. Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Non-Small-Cell Lung / metabolism. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Growth Differentiation Factor 5. Humans. Transforming Growth Factor beta / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Thorac Surg. 2005 Sep;80(3):1032 [16122480.001]
  • (PMID = 16122479.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA91919-01A1
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / BMP2 protein, human; 0 / BMP4 protein, human; 0 / BMP6 protein, human; 0 / BMP7 protein, human; 0 / Bone Morphogenetic Protein 2; 0 / Bone Morphogenetic Protein 4; 0 / Bone Morphogenetic Protein 6; 0 / Bone Morphogenetic Protein 7; 0 / Bone Morphogenetic Proteins; 0 / GDF5 protein, human; 0 / Growth Differentiation Factor 5; 0 / Transforming Growth Factor beta
  •  go-up   go-down


22. Ozcanli H, Ozdemir H, Ozenci AM, Söyüncü Y, Aydin AT: [Metastatic tumors of the hand in three cases]. Acta Orthop Traumatol Turc; 2005;39(5):445-8
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metastatic tumors of the hand in three cases].
  • Metastatic malignancies of the hand are rare and they usually develop from lung, breast, and kidney tumors.
  • We presented three patients with metastatic tumors of the hand, whose ages were 58 (male), 42 (female), and 40 (male) years.
  • Metastases developed in the thumb and the big toe, metacarpal bone, and the nail bed following treatment for primary tumors of the bladder, colon, and chondrosarcoma of the proximal femur, respectively.
  • [MeSH-major] Adenocarcinoma / diagnosis. Bone Neoplasms / diagnosis. Hand
  • [MeSH-minor] Adult. Colonic Neoplasms / diagnosis. Colonic Neoplasms / pathology. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16531705.001).
  • [ISSN] 1017-995X
  • [Journal-full-title] Acta orthopaedica et traumatologica turcica
  • [ISO-abbreviation] Acta Orthop Traumatol Turc
  • [Language] tur
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Turkey
  • [Number-of-references] 25
  •  go-up   go-down


23. Yanagitani N, Kaira K, Ishizuka T, Aoki H, Utsugi M, Shimizu Y, Sunaga N, Endou K, Hisada T, Mori M: Multiple lung metastases presenting as ground-glass opacities in a pulmonary adenocarcinoma: a case report. Cases J; 2009;2:6910

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple lung metastases presenting as ground-glass opacities in a pulmonary adenocarcinoma: a case report.
  • INTRODUCTION: Focal ground-glass opacity on computed tomography suggests several disorders including inflammatory disease, fibrosis, or a primary lung neoplastic lesion, metastatic lung tumor.
  • CASE PRESENTATION: The case of a 55-year-old female presenting with adenocarcinoma of the lung is herein reported.
  • Computed tomography of the chest revealed a primary mass lesion in the upper lobe of the right lung and multiple metastases presenting as ground-glass opacities.
  • Macroscopic metastases were observed in the bone, the hilar and mediastinal lymph nodes, and another lobe.
  • This case was advanced lung cancer.
  • CONCLUSION: A metastatic lung tumor showing ground-glass opacity is uncommon.
  • It is quite difficult to distinguish between multiple primary lung cancers and intrapulmonary metastasis when patients present with multiple lung nodules.
  • A lot of clinical information is therefore required to make an accurate diagnosis in such cases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Thorac Surg. 2005 Jan;79(1):e1-2 [15620900.001]
  • [Cites] Ann Thorac Surg. 2006 Oct;82(4):1508-10 [16996967.001]
  • (PMID = 19829882.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2740189
  •  go-up   go-down


24. Hayashi M, Tsuchiya H, Yamamoto N, Karita M, Shirai T, Nishida H, Takeuchi A, Tomita K: Caffeine-potentiated chemotherapy for metastatic carcinoma and lymphoma of bone and soft tissue. Anticancer Res; 2005 May-Jun;25(3c):2399-405
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caffeine-potentiated chemotherapy for metastatic carcinoma and lymphoma of bone and soft tissue.
  • In that series, patients with metastatic carcinoma or lymphoma were treated with caffeine-potentiated chemotherapy.
  • PATIENTS AND METHODS: Five patients with metastatic carcinoma or lymphoma were treated with caffeine-potentiated chemotherapy.
  • RESULTS: Primary tumors were diagnosed as breast cancer, adenocarcinoma of the lung, clear cell adenocarcinoma of the vagina, diffuse large B-cell lymphoma and gastric cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Caffeine / pharmacology. Carcinoma / drug therapy. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Aged. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Drug Synergism. Female. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Male. Middle Aged. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology. Vaginal Neoplasms / drug therapy. Vaginal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Caffeine.
  • Hazardous Substances Data Bank. CAFFEINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16080466.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 3G6A5W338E / Caffeine
  •  go-up   go-down


25. Uruga H, Morokawa N, Enomoto T, Takaya H, Miyamoto A, Kishi K, Kurosaki A, Fujii T, Yoshimura K: [A case of pulmonary tumor thrombotic microangiopathy associated with lung adenocarcinoma diagnosed by CT-guided lung biopsy]. Nihon Kokyuki Gakkai Zasshi; 2008 Nov;46(11):928-33
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of pulmonary tumor thrombotic microangiopathy associated with lung adenocarcinoma diagnosed by CT-guided lung biopsy].
  • CT-guided lung biopsy from the right lower lobe revealed tumor cell embolism, intimal fibrocellular proliferation of small arteries, fibrin thrombi and recanalization.
  • Embolic tumor cells were adenocarcinoma and immunohistologial staining for TTF-1 was positive.
  • The patient was diagnosed as having pulmonary tumor thrombotic microangiopathy (PTTM) associated with clinical stage IV primary lung adenocarcinoma.
  • Although chemotherapy with carboplatin and paclitaxel resulted in improvement of pulmonary consolidations, multiple bone metastatic lesions appeared.
  • This was the first reported case of PTTM associated with lung cancer and diagnosed antemortem by CT-guided biopsy.
  • This suggests that CT-guided lung biopsy may be useful for diagnosis of PTTM, and enable establishment of appropriate cancer chemotherapy.
  • [MeSH-major] Adenocarcinoma / pathology. Biopsy / methods. Lung / blood supply. Lung Neoplasms / pathology. Neoplastic Cells, Circulating / pathology. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19068768.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


26. Ahlmann ER, Greene NW, Menendez LR, Stevanovic MV: Unusual locations for metastatic malignancy of the hand: a report of three cases. J Surg Orthop Adv; 2008;17(4):267-70
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual locations for metastatic malignancy of the hand: a report of three cases.
  • Metastatic tumors of the hand bones are very rare.
  • This report presents three cases of metastatic lesions involving the bones of the hand.
  • These metastases, with adenocarcinoma of the lung as the primary malignancy, were the first clinical presentation of adenocarcinoma in two of these patients.
  • The hamate bone was involved in one patient and the proximal phalanx of the ring finger was involved in the other patient.
  • The third patient developed metastatic disease to the distal phalanx 8 months after initial diagnosis.
  • The authors emphasize that a lytic lesion in the hand may be the first clinical sign of a malignancy or progression to metastatic disease.
  • [MeSH-major] Adenocarcinoma / pathology. Bone Neoplasms / secondary. Finger Phalanges. Hamate Bone. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19138500.001).
  • [ISSN] 1548-825X
  • [Journal-full-title] Journal of surgical orthopaedic advances
  • [ISO-abbreviation] J Surg Orthop Adv
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Katakami N: [Lung cancer with bone metastasis]. Gan To Kagaku Ryoho; 2006 Aug;33(8):1049-53
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lung cancer with bone metastasis].
  • Lung cancer is one of the most common solid tumors to develop metastases to bone.
  • The prognosis of patients with metastatic lung cancer to bones is short,usually less than 6 months.
  • Radiotherapy for metastatic bone tumor is a mainstay to relieve pain and control the localized disease.
  • Prophylactic fixation for long bone fractures is recommended in cases where 30 to 50% of the cortex has been destroyed, pain is present after radiotherapy, or life expectancy is more than 3 months.
  • Systemic chemotherapy has been proved to prolong survival of patients with metastatic non-small-cell lung cancer (NSCLC) as well as extensive small cell lung cancer (SCLC).
  • Gefitinib in upfront or second-line treatment is an optional therapy in adenocarcinoma patients without a history of smoking.
  • The third generation bisphosphonate zoledronate has been demonstrated to improve cancer pain and to prevent skeletal morbidity in lung cancer patients with metastatic bone disease.
  • [MeSH-major] Analgesics / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / secondary. Lung Neoplasms / pathology. Lung Neoplasms / radiotherapy. Pain, Intractable / drug therapy
  • [MeSH-minor] Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Carboplatin / administration & dosage. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / radiotherapy. Carcinoma, Non-Small-Cell Lung / secondary. Carcinoma, Non-Small-Cell Lung / surgery. Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / radiotherapy. Carcinoma, Small Cell / secondary. Carcinoma, Small Cell / surgery. Cisplatin / administration & dosage. Combined Modality Therapy. Diphosphonates / therapeutic use. Drug Administration Schedule. Etoposide / administration & dosage. Fractures, Bone / prevention & control. Humans. Paclitaxel / administration & dosage. Prognosis. Quinazolines / administration & dosage. Radiotherapy Dosage. Taxoids / administration & dosage

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16912519.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Analgesics; 0 / Diphosphonates; 0 / Quinazolines; 0 / Taxoids; 15H5577CQD / docetaxel; 6PLQ3CP4P3 / Etoposide; 7673326042 / irinotecan; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; S65743JHBS / gefitinib; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


28. Wang CY, Zhang XY: [(99m)Tc-MDP wholebody bone imaging in evaluation of the characteristics of bone metastasis of primary lung cancer]. Zhonghua Zhong Liu Za Zhi; 2010 May;32(5):382-6
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [(99m)Tc-MDP wholebody bone imaging in evaluation of the characteristics of bone metastasis of primary lung cancer].
  • OBJECTIVE: To explore the image characteristics of bone metastasis of primary lung carcinoma.
  • METHODS: Whole-body bone imaging ((99)Tc(m)-MDP) was performed in 258 patients with pathologically proven lung carcinoma.
  • The rate of bone metastasis, distribution of the metastatic lesions and their characteristics were analyzed.
  • RESULTS: Among the 258 cases, 142 patients developed bone metastasis.
  • The overall rate of bone metastasis was 55.0%.
  • Ribs, thoracic vertebrae, ilium and lumbar vertebrae had a higher rate of bone metastasis, higher than 20%, respectively.
  • 1224 bone metastatic foci (97.8%) were presented as strong radioactive, 26 (2.1%) mixed lesion, and 2 (0.2%) low radioactive.
  • The accumulative bone metastasis rate was 28.7% for the patients with one to three lesions.
  • The metastasis rate decreased gradually with the increasing number of metastatic lesions.
  • CONCLUSION: Bone metastasis is very common in patients with lung cancer.
  • Most bone metastases are characterized by strong radioactive and earlier punctate form, often occurs in the trunk bones of axial skeleton or appendicular girdles.
  • The distribution of earlier metastases has not obvious regularity, and advanced bone metastases are often concurrent, multiple and multiform, widely and randomly distributed in the body.
  • [MeSH-major] Bone Neoplasms / radionuclide imaging. Bone Neoplasms / secondary. Technetium Tc 99m Medronate. Tomography, Emission-Computed, Single-Photon. Whole Body Imaging
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / radionuclide imaging. Adult. Aged. Aged, 80 and over. Bone and Bones / pathology. Bone and Bones / radionuclide imaging. Female. Humans. Lung Neoplasms / pathology. Lung Neoplasms / radionuclide imaging. Male. Middle Aged. Radiopharmaceuticals

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20723439.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; X89XV46R07 / Technetium Tc 99m Medronate; Adenocarcinoma of lung
  •  go-up   go-down


29. Kocak M, Mayadagli A, Ozkan A, Parlak C, Demir O, Marti A, Dogan Eren M, Kaya S, Gumus M: Outcome of metastatic non-small cell lung carcinoma patients receiving docetaxelcisplatin combination chemotherapy: single institution experience. J BUON; 2007 Oct-Dec;12(4):471-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of metastatic non-small cell lung carcinoma patients receiving docetaxelcisplatin combination chemotherapy: single institution experience.
  • PURPOSE: Despite advances in the detection and treatment, the long-term survival of patients with advanced nonsmall cell lung cancer (NSCLC) remains poor, with a 5-year overall survival (OS) of less than 5%.
  • We conducted this observational study to determine the influence of docetaxel plus cisplatin combination chemotherapy on response, time to progression (TTP) and OS, and to evaluate its tolerability in chemotherapy-naïve patients with metastatic NSCLC.
  • PATIENTS AND METHODS: Patients with histologically or cytologically confirmed stage IV NSCLC who met the following criteria were eligible for the study: no previous chemotherapy, Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2, objectively measurable disease, adequate bone marrow reserve, normal hepatic and renal function.
  • Histological type was squamous cell carcinoma in 21 (42%) patients, adenocarcinoma in 11 (22%) and undifferentiated carcinoma in 18 (36%).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Cisplatin / administration & dosage. Lung Neoplasms / drug therapy. Taxoids / administration & dosage

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18067204.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


30. Segawa N, Abe H, Nishida T, Katsuoka Y: [A case of prostatic cancer discovered from lung metastatic lesions]. Hinyokika Kiyo; 2006 Feb;52(2):147-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of prostatic cancer discovered from lung metastatic lesions].
  • We report a case in a 70-year-old patient indicated to have a metastatic lesion from a chest X-ray taken during a medical examination.
  • Transrectal sextant needle biopsy of the prostate was performed, revealing moderately differentiated adenocarcinoma.
  • Computed tomography (CT) scan and bone scintigraphy showed intrapelvic lymphnode adenopathy and metastasis to the right pubic bone.
  • Under a diagnosis of stage D2 prostate cancer, we initiated endocrine therapy (luteinizing hormone-releasing hormone analogue depot every 4 weeks and bicalutamide).
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Agents, Hormonal / administration & dosage. Lung Neoplasms / secondary. Prostate-Specific Antigen / blood. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / pathology


31. Husain A, Blumenschein G, Esmaeli B: Treatment and outcomes for metastatic sebaceous cell carcinoma of the eyelid. Int J Dermatol; 2008 Mar;47(3):276-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment and outcomes for metastatic sebaceous cell carcinoma of the eyelid.
  • OBJECTIVE: To report the management and outcomes in patients with metastatic eyelid sebaceous cell carcinoma.
  • METHODS: The clinical records of four patients with metastatic eyelid sebaceous cell carcinoma treated between January 1999 and August 2006 were reviewed.
  • Metastatic sites included the lung in three patients, regional lymph nodes in two, liver in two, and bone in one.
  • Time from diagnosis of eyelid carcinoma to metastasis ranged from 0 to 62 months.
  • One patient developed lung metastasis 5 years after the diagnosis of eyelid tumor; she was treated with systemic chemotherapy followed by subtotal lung resection.
  • The follow-up time from diagnosis of metastasis to last contact or death ranged from 1 month to 3 years (median of 21 months).
  • Treatment of metastatic disease may include a combination of chemotherapy, radiation, and surgical neck dissection.
  • [MeSH-major] Adenocarcinoma, Sebaceous / secondary. Bone Neoplasms / secondary. Eyelid Neoplasms / pathology. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Parotid Neoplasms / secondary. Sebaceous Gland Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma, Basal Cell / diagnosis. Chalazion / diagnosis. Diagnostic Errors. Female. Humans. Lymphatic Metastasis / radiotherapy. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18289332.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Frankel BM, Jones T, Wang C: Segmental polymethylmethacrylate-augmented pedicle screw fixation in patients with bone softening caused by osteoporosis and metastatic tumor involvement: a clinical evaluation. Neurosurgery; 2007 Sep;61(3):531-7; discussion 537-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Segmental polymethylmethacrylate-augmented pedicle screw fixation in patients with bone softening caused by osteoporosis and metastatic tumor involvement: a clinical evaluation.
  • OBJECTIVE: Instrumentation of the osteoporotic spine may result in bone failure because of pedicle screw loosening and pullout.
  • A clinical evaluation of a novel fenestrated bone tap used in pedicle screw augmentation was performed to determine the performance and safety of this technique.
  • Of these patients, 23 had bone softening secondary to osteoporosis and/or metastatic spinal tumor involvement.
  • RESULTS: Six patients (26%) had metastatic spine disease (squamous cell lung carcinoma, renal cell carcinoma, bladder carcinoma, breast, prostate, and uterine adenocarcinoma); five patients (22%) had a degenerative spondylolisthesis; and 12 patients (52%) had burst fractures, eight as a result of benign causes and four as a result of metastatic disease.
  • Four (17%) patients underwent revision surgery of previous pedicle screw failure resulting from bone softening and pseudarthrosis.
  • [MeSH-major] Bone Density. Bone Screws / standards. Osteoporosis / surgery. Polymethyl Methacrylate / standards. Spinal Neoplasms / surgery

  • Genetic Alliance. consumer health - Osteoporosis.
  • MedlinePlus Health Information. consumer health - Bone Density.
  • MedlinePlus Health Information. consumer health - Osteoporosis.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17881965.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9011-14-7 / Polymethyl Methacrylate
  •  go-up   go-down


33. O'Reilly EM, Niedzwiecki D, Hall M, Hollis D, Bekaii-Saab T, Pluard T, Douglas K, Abou-Alfa GK, Kindler HL, Schilsky RL, Goldberg RM, Cancer and Leukemia Group B: A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). Oncologist; 2010;15(12):1310-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603).
  • BACKGROUND: The Cancer and Leukemia Group B (CALGB) conducted a phase II study evaluating sunitinib in patients with progressive metastatic pancreas adenocarcinoma following prior gemcitabine-based therapy (trial CALGB 80603; ClinicalTrials.gov identifier, NCT00397787).
  • PATIENTS AND METHODS: Patients aged ≥18 years with an Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2 and with progressive pancreas adenocarcinoma following treatment with gemcitabine were eligible.
  • CONCLUSIONS: The study met its primary endpoint; however sunitinib had minimal activity and moderate toxicity in a population of gemcitabine-refractory pancreas adenocarcinoma patients.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Indoles / therapeutic use. Pancreatic Neoplasms / drug therapy. Pyrroles / therapeutic use. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Female. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 May 15;88(10):2239-45 [10820344.001]
  • [Cites] J Clin Oncol. 2009 Jan 10;27(2):193-8 [19047305.001]
  • [Cites] Cancer. 2004 Jul 1;101(1):133-8 [15221998.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] Eur J Cancer. 1998 Aug;34(9):1439-47 [9849429.001]
  • [Cites] Clin Cancer Res. 2009 Mar 15;15(6):1873-82 [19276273.001]
  • [Cites] Oncology. 2009;76(4):254-61 [19246950.001]
  • [Cites] J Clin Oncol. 2009 May 1;27(13):2231-7 [19307500.001]
  • [Cites] Science. 2009 Jun 12;324(5933):1457-61 [19460966.001]
  • [Cites] Curr Drug Metab. 2009 Jun;10(5):470-81 [19689244.001]
  • [Cites] J Gastrointest Cancer. 2009;40(1-2):1-9 [19513861.001]
  • [Cites] Expert Rev Anticancer Ther. 2009 Oct;9(10):1473-85 [19828009.001]
  • [Cites] Expert Rev Anticancer Ther. 2009 Oct;9(10):1487-97 [19828010.001]
  • [Cites] J Clin Oncol. 2010 Aug 1;28(22):3617-22 [20606091.001]
  • [Cites] Cancer Chemother Pharmacol. 2010 Nov;66(6):1051-7 [20130876.001]
  • [Cites] Ann Oncol. 1999;10 Suppl 4:69-73 [10436789.001]
  • [Cites] Curr Opin Investig Drugs. 2004 Dec;5(12):1329-39 [15648955.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3509-16 [15908661.001]
  • [Cites] Invest New Drugs. 2005 Aug;23(4):369-75 [16012797.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8033-40 [16258101.001]
  • [Cites] Jpn J Clin Oncol. 2007 Feb;37(2):114-20 [17272317.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] Gut. 2007 Aug;56(8):1134-52 [17625148.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4787-92 [17947726.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):463-7 [18202421.001]
  • [Cites] BMC Cancer. 2008;8:82 [18373843.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Sep;62(4):673-8 [18172650.001]
  • [Cites] Cancer. 2008 Oct 15;113(8):2046-52 [18756532.001]
  • [Cites] J Gastrointest Surg. 2002 Mar-Apr;6(2):159-66; discussion 166 [11992800.001]
  • (PMID = 21148613.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00397787
  • [Grant] United States / NCI NIH HHS / CA / U10 CA047577; United States / NCI NIH HHS / CA / U10 CA032291; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA77597; United States / NCI NIH HHS / CA / CA11789; United States / NCI NIH HHS / CA / U10 CA077658; United States / NCI NIH HHS / CA / CA77406; United States / NCI NIH HHS / CA / CA47577; United States / NCI NIH HHS / CA / CA35113; United States / NCI NIH HHS / CA / CA32291; United States / NCI NIH HHS / CA / U10 CA086726; United States / NCI NIH HHS / CA / CA41287; United States / NCI NIH HHS / CA / U10 CA035279; United States / NCI NIH HHS / CA / U10 CA045808; United States / NCI NIH HHS / CA / U10 CA031946; United States / NCI NIH HHS / CA / CA77651; United States / NCI NIH HHS / CA / U10 CA033601; United States / NCI NIH HHS / CA / U10 CA045389; United States / NCI NIH HHS / CA / CA45389; United States / NCI NIH HHS / CA / U10 CA077597; United States / NCI NIH HHS / CA / CA45808; United States / NCI NIH HHS / CA / CA35279; United States / NCI NIH HHS / CA / U10 CA045418; United States / NCI NIH HHS / CA / CA86726; United States / NCI NIH HHS / CA / U10 CA077440; United States / NCI NIH HHS / CA / CA77440; United States / NCI NIH HHS / CA / U10 CA041287; United States / NCI NIH HHS / CA / U10 CA035113; United States / NCI NIH HHS / CA / U10 CA077651; United States / NCI NIH HHS / CA / CA04326; United States / NCI NIH HHS / CA / CA08025; United States / NCI NIH HHS / CA / CA47642; United States / NCI NIH HHS / CA / CA45418; United States / NCI NIH HHS / CA / CA77658; United States / NCI NIH HHS / CA / CA77298; United States / NCI NIH HHS / CA / U10 CA047642; United States / NCI NIH HHS / CA / CA31946
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Indoles; 0 / Pyrroles; V99T50803M / sunitinib
  • [Other-IDs] NLM/ PMC3227926
  •  go-up   go-down


34. Gong Y, Ren L, Zhou L, Zhu J, Huang M, Zhou X, Wang J, Lu Y, Hou M, Wei Y: Phase II evaluation of nedaplatin and paclitaxel in patients with metastatic esophageal carcinoma. Cancer Chemother Pharmacol; 2009 Jul;64(2):327-33
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II evaluation of nedaplatin and paclitaxel in patients with metastatic esophageal carcinoma.
  • PURPOSE: To evaluate the efficiency and toxicities of nedaplatin and paclitaxel in patients with metastatic carcinoma of the esophagus.
  • METHODS: Thirty-nine untreated patients with confirmed metastatic tumors were enrolled.
  • CONCLUSION: Comparing to other regimens, combination of nedaplatin and paclitaxel achieved an encouraging clinical outcome, with relatively minimal toxicities for patients with metastatic esophageal carcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Esophageal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Female. Follow-Up Studies. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Paclitaxel / administration & dosage. Prognosis. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19048253.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 8UQ3W6JXAN / nedaplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


35. Li XF, Zanzonico P, Ling CC, O'Donoghue J: Visualization of experimental lung and bone metastases in live nude mice by X-ray micro-computed tomography. Technol Cancer Res Treat; 2006 Apr;5(2):147-55
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Visualization of experimental lung and bone metastases in live nude mice by X-ray micro-computed tomography.
  • The objective of this study was to evaluate the utility of micro-computed tomography (micro-CT) for the detection and monitoring of experimental lung and bone metastases in nude mice.
  • Whole body micro-CT scans were performed in lung or bone metastasis-bearing nude mice under deep anesthesia.
  • The volumes of individual lung metastases were estimated by micro-CT, and compared to direct measurements on excised tumors.
  • The smallest lung tumor detected was 0.85 mm in diameter.
  • The progression of metastatic lung disease, including tumor growth and the development of pleural effusion, was visualized by serial micro-CT scans in live mice.
  • Bone lesions identified by micro-CT were confirmed as metastases by histopathological examination.
  • Micro-CT may be used as an accurate, noninvasive tool to detect and monitor experimental bone and lung metastases in intact live nude mice.
  • [MeSH-major] Adenocarcinoma / radiography. Bone Neoplasms / radiography. Lung Neoplasms / radiography. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16551134.001).
  • [ISSN] 1533-0346
  • [Journal-full-title] Technology in cancer research & treatment
  • [ISO-abbreviation] Technol. Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Yasar F, Oz G, Dolanmaz D, Akgünlü F: Mandibular metastasis in a patient with pulmonary adenocarcinoma. Dentomaxillofac Radiol; 2006 Sep;35(5):383-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mandibular metastasis in a patient with pulmonary adenocarcinoma.
  • Metastatic tumour spread to the mandible is quite rare.
  • We report a case of distant metastasis of pulmonary adenocarcinoma in the mandibular bone.
  • The patient had pain in his left mandibular premolar-molar area caused by a mandibular metastasis from a previously undiagnosed pulmonary adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Lung Neoplasms / pathology. Mandibular Neoplasms / secondary
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16940489.001).
  • [ISSN] 0250-832X
  • [Journal-full-title] Dento maxillo facial radiology
  • [ISO-abbreviation] Dentomaxillofac Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


37. Anoop TM, George S, Divya KP, Jabbar PK: Metastatic phalangeal osteolysis as an initial presentation of carcinoma colon. Am J Surg; 2010 Nov;200(5):e61-3
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic phalangeal osteolysis as an initial presentation of carcinoma colon.
  • Metastatic malignancies of the hand are rare and usually develop from lung, breast, or kidney tumors.
  • The authors report a case of differentiated adenocarcinoma of the colon in a 76-year-old man who presented with distal phalangeal metastasis and osteolysis in the form of a painful swelling at the tip of the right little finger of 6 months duration.
  • Diagnosis was confirmed by biopsy.
  • [MeSH-major] Adenocarcinoma / secondary. Bone Neoplasms / secondary. Colonic Neoplasms / pathology. Finger Phalanges. Osteolysis / etiology
  • [MeSH-minor] Aged. Biopsy. Diagnosis, Differential. Fatal Outcome. Humans. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20870210.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Ak I, Sivrikoz MC, Entok E, Vardareli E: Discordant findings in patients with non-small-cell lung cancer: absolutely normal bone scans versus disseminated bone metastases on positron-emission tomography/computed tomography. Eur J Cardiothorac Surg; 2010 Apr;37(4):792-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discordant findings in patients with non-small-cell lung cancer: absolutely normal bone scans versus disseminated bone metastases on positron-emission tomography/computed tomography.
  • OBJECTIVE: At present, metastatic bone involvement is usually assessed using bone scintigraphy, which has a high sensitivity but a poor specificity.
  • The objective of our study was to compare the sensibility of the 2-deoxy-2-[18F] fluoro-d-glucose positron emission tomography/computed tomography (F-18 FDG PET/CT) for the detection of bone metastasis in patients with non-small-cell lung cancer (NSCLC) whose technetium 99m methylenediphosphonate (Tc-99m MDP) bone scans were absolutely normal.
  • MATERIAL AND METHODS: This study based on the retrospective analysis of 95 consecutive patients with histologically proven NSCLC who underwent F-18 FDG PET/CT and Tc-99m MDP bone scan at the Eskişehir Osmangazi University School of Medicine, Department of Nuclear Medicine between November 2006 and October 2008.
  • Nineteen patients (19 of 95, 20%) with absolutely normal Tc-99m bone scan versus multiple high-grade F-18 FDG avid bony metastases on F-18 FDG PET/CT were selected for the review.
  • RESULTS: Nine patients had squamous cell carcinoma, six had adenocarcinoma, three had large cell carcinoma and one had adenosquamous cell carcinoma.
  • Tc-99m MDP bone scan that did not reveal bony abnormalities or radiotracer uptake was characteristic of benign disease (defined as absolutely normal) in these patients.
  • Whereas, F-18 FDG PET/CT not only showed extremely disseminated heterogeneous nest-like high-grade FDG avid metastatic foci within the marrow cavity of the upper and lower thoracic spine, lumbar spine, pelvis, rib cages and bilateral proximal long bones, but also showed disseminated osteolytic bony metastases in these areas.
  • CONCLUSION: Discordant findings of skeletal metastasis between Tc-99m MDP bone scans and F-18 FDG PET/CT imaging may be seen in 20% of the patients with NSCLC.
  • F-18 FDG PET/CT could detect metastatic bone involvement more accurately than bone scintigraphy.
  • Bone scans are insensitive to early bone marrow neoplastic infiltration.
  • Assessment of glucose metabolism with FDG PET/CT can represent a more powerful tool to detect early bone metastases in lung cancer than with traditional bone scans.
  • [MeSH-major] Bone Neoplasms / secondary. Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • Genetic Alliance. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20015657.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; X89XV46R07 / Technetium Tc 99m Medronate
  •  go-up   go-down


39. Gurel B, Ali TZ, Montgomery EA, Begum S, Hicks J, Goggins M, Eberhart CG, Clark DP, Bieberich CJ, Epstein JI, De Marzo AM: NKX3.1 as a marker of prostatic origin in metastatic tumors. Am J Surg Pathol; 2010 Aug;34(8):1097-105
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NKX3.1 as a marker of prostatic origin in metastatic tumors.
  • Although most studies have shown that staining for NKX3.1 protein is positive in the majority of primary prostatic adenocarcinomas, it has been shown to be downregulated in many high-grade prostate cancers, and completely lost in the majority of metastatic prostate cancers (eg, in 65% to 78% of lesions).
  • A recent study showed that NKX3.1 staining with a novel antibody was highly sensitive and specific for high-grade prostatic adenocarcinoma when compared with high-grade urothelial carcinoma.
  • This raised the question that this antibody may perform better than earlier used antibodies in metastatic prostate tumors.
  • However, the sensitivity and specificity for prostate carcinomas for this antibody in metastatic lesions was not determined.
  • Although prostate-specific antigen (PSA) and prostatic-specific acid phosphatase (PSAP) are excellent tissue markers of prostate cancer, at times they may be expressed at low levels, focally, or not at all in poorly differentiated primary and metastatic prostatic adenocarcinomas.
  • The purpose of this study was to determine the performance of NKX3.1 as a marker of metastatic adenocarcinoma of prostatic origin.
  • Immunohistochemical staining against NKX3.1, PSA, and PSAP was carried out on a tissue microarray (TMA) (0.6-mm tissue cores) of hormone naïve metastatic prostate adenocarcinoma specimens from lymph nodes, bone, and soft tissue.
  • To determine the specificity of NKX3.1 for prostatic adenocarcinoma, we used TMAs that contained cancers from various sites including the urinary bladder, breast, colon, salivary gland, stomach, pancreas, thyroid, and central nervous system, and standard paraffin sections of cancers from other sites including the adrenal cortex, kidney, liver, lung, and testis.
  • The sensitivity for identifying metastatic prostatic adenocarcinomas overall was 98.6% (68/69 cases positive) for NKX3.1, 94.2% (65/69 cores positive) for PSA, and 98.6% (68/69 cores positive) for PSAP.
  • NKX3.1 seems to be a highly sensitive and specific tissue marker of metastatic prostatic adenocarcinoma.
  • In the appropriate clinical setting, the addition of IHC staining for NKX3.1, along with other prostate-restricted markers, may prove to be a valuable adjunct to definitively determine prostatic origin in poorly differentiated metastatic carcinomas.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2000 Mar;163(3):972-9 [10688034.001]
  • [Cites] Arch Pathol Lab Med. 2008 Sep;132(9):1388-96 [18788849.001]
  • [Cites] Dev Dyn. 2000 Oct;219(2):248-60 [11002344.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):6111-5 [11085535.001]
  • [Cites] J Urol. 2001 Apr;165(4):1329-34 [11257711.001]
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1397-404 [11684956.001]
  • [Cites] Mol Cell Biol. 2002 Mar;22(5):1495-503 [11839815.001]
  • [Cites] Urology. 2001 Jun;57(6):1179-83 [11377343.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2884-9 [11854455.001]
  • [Cites] JAMA. 2002 Apr 3;287(13):1662-70 [11926890.001]
  • [Cites] Cancer Res. 2002 Apr 15;62(8):2220-6 [11956072.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):2999-3004 [12036903.001]
  • [Cites] Prostate. 2003 May 1;55(2):111-7 [12661036.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):3886-90 [12873978.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1607-14 [15111307.001]
  • [Cites] Mod Pathol. 2004 Mar;17(3):307-15 [14739905.001]
  • [Cites] Prostate. 2004 Aug 1;60(3):246-56 [15176054.001]
  • [Cites] J Urol. 2004 Sep;172(3):1134-9 [15311057.001]
  • [Cites] Am J Clin Pathol. 2004 Aug;122(2):275-89 [15323145.001]
  • [Cites] Prostate. 2004 Nov 1;61(3):215-27 [15368473.001]
  • [Cites] Cancer Res. 1993 Sep 1;53(17):3869-73 [7689419.001]
  • [Cites] Cancer Res. 1994 Jun 15;54(12):3273-7 [7515768.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Jul;10(3):151-9 [7522037.001]
  • [Cites] Cancer Res. 1995 Jul 15;55(14):2959-62 [7606709.001]
  • [Cites] Genes Chromosomes Cancer. 1995 Jul;13(3):168-74 [7669736.001]
  • [Cites] Cancer Res. 1996 May 15;56(10):2411-6 [8625320.001]
  • [Cites] Urology. 1997 Oct;50(4):643-7 [9338751.001]
  • [Cites] Cancer Res. 1997 Oct 15;57(20):4455-9 [9377551.001]
  • [Cites] Urology. 1998 Oct;52(4):637-40 [9763084.001]
  • [Cites] Clin Cancer Res. 1997 Jan;3(1):81-5 [9815541.001]
  • [Cites] Cancer. 1998 Dec 1;83(11):2259-69 [9840525.001]
  • [Cites] Genes Dev. 1999 Apr 15;13(8):966-77 [10215624.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1164-73 [15734999.001]
  • [Cites] Histopathology. 2005 Jul;47(1):1-16 [15982318.001]
  • [Cites] Ann N Y Acad Sci. 2005 Nov;1059:33-40 [16382041.001]
  • [Cites] Semin Diagn Pathol. 2005 Feb;22(1):88-104 [16512601.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10683-90 [17108105.001]
  • [Cites] Histopathology. 2007 Mar;50(4):472-83 [17448023.001]
  • [Cites] Am J Surg Pathol. 2007 Aug;31(8):1246-55 [17667550.001]
  • [Cites] Am J Surg Pathol. 2007 Sep;31(9):1351-5 [17721190.001]
  • [Cites] Am J Surg Pathol. 2008 Sep;32(9):1322-6 [18670358.001]
  • [Cites] Differentiation. 2008 Jul;76(6):717-27 [18557759.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1677-82 [10749139.001]
  • (PMID = 20588175.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA058236-16; United States / NCI NIH HHS / CA / P50 CA058236; United States / NCI NIH HHS / CA / P30 CA006973; United States / NCI NIH HHS / CA / P50 CA058236-16; United States / NCI NIH HHS / CA / P50 CA058236-07; United States / NCI NIH HHS / CA / P50 CA58236
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Homeodomain Proteins; 0 / NKX3-1 protein, human; 0 / Transcription Factors; EC 3.1.3.2 / Acid Phosphatase; EC 3.1.3.2 / prostatic acid phosphatase; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Other-IDs] NLM/ NIHMS272269; NLM/ PMC3072223
  •  go-up   go-down


40. Recchia F, Candeloro G, Necozione S, Bratta M, Bisegna R, Rea S: Alternating XELFOX and XELFIRI in patients with metastatic colorectal cancer. Am J Clin Oncol; 2008 Aug;31(4):323-8
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alternating XELFOX and XELFIRI in patients with metastatic colorectal cancer.
  • BACKGROUND: To evaluate the antitumor activity and toxicity of 5-fluorouracil (FU)/leucovorin (LV) and capecitabine (C) given with either oxaliplatin (OX) or camptothecin (CPT-11) in the treatment of chemotherapy naive patients with metastatic colorectal cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Camptothecin / administration & dosage. Capecitabine. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Humans. Leucovorin / administration & dosage. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Middle Aged. Organoplatinum Compounds / administration & dosage. Prognosis. Prospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18845989.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


41. Gomez-Roca C, Raynaud CM, Penault-Llorca F, Mercier O, Commo F, Morat L, Sabatier L, Dartevelle P, Taranchon E, Besse B, Validire P, Italiano A, Soria JC: Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites. J Thorac Oncol; 2009 Oct;4(10):1212-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites.
  • The correlation of biomarker expression between the primary tumor and its corresponding metastasis has not yet been well documented and analyzed in patients with non-small cell lung cancer (NSCLC).
  • [MeSH-major] Adrenal Gland Neoplasms / metabolism. Biomarkers, Tumor / metabolism. Bone Neoplasms / metabolism. Brain Neoplasms / metabolism. Carcinoma, Non-Small-Cell Lung / metabolism. Lung Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma, Bronchiolo-Alveolar / metabolism. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Large Cell / metabolism. Carcinoma, Large Cell / pathology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. DNA-Binding Proteins / metabolism. Endonucleases / metabolism. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Staging. Prognosis. Receptor, Epidermal Growth Factor / metabolism. Receptors, Vascular Endothelial Growth Factor / metabolism. Survival Rate. Vascular Endothelial Growth Factor A / metabolism


42. Krupitskaya Y, Eslamy HK, Nguyen DD, Kumar A, Wakelee HA: Osteoblastic bone flare on F18-FDG PET in non-small cell lung cancer (NSCLC) patients receiving bevacizumab in addition to standard chemotherapy. J Thorac Oncol; 2009 Mar;4(3):429-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteoblastic bone flare on F18-FDG PET in non-small cell lung cancer (NSCLC) patients receiving bevacizumab in addition to standard chemotherapy.
  • Positron emission tomography (PET) is used routinely to follow therapeutic response in patients treated for non-small cell lung cancer (NSCLC).
  • In other disease entities though, isolated cases have been documented of asynchronous increases in activity in metastatic bone lesions ("bone flare") despite evidence of therapeutic response or stability in other lesions.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bone Neoplasms / radionuclide imaging. Bone Neoplasms / secondary. Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / radionuclide imaging. Adenocarcinoma / secondary. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. Biopsy, Needle. Female. Fluorodeoxyglucose F18. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Osteoblasts / pathology. Positron-Emission Tomography / methods. Risk Assessment. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • Genetic Alliance. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19247091.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


43. Parlea L, Fahim L, Munoz D, Hanna A, Anderson J, Cusimano M, Kovacs K, Gardiner G: Follicular carcinoma of the thyroid with aggressive metastatic behavior in a pregnant woman: report of a case and review of the literature. Hormones (Athens); 2006 Oct-Dec;5(4):295-302
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular carcinoma of the thyroid with aggressive metastatic behavior in a pregnant woman: report of a case and review of the literature.
  • We report the clinical and pathological features of a 33-year old pregnant patient with follicular carcinoma of the thyroid who presented with widespread bone and lung metastases at the time of diagnosis. the resected tumor had a focal insular component that showed extensive vascular invasion spreading beyond the thyroid capsule, and was associated with widespread bone and lung metastases.
  • We suggest that architectural differentiation of the tumor and cell proliferation rate are not reliable markers of metastatic behavior in this particular thyroid neoplasm.
  • Microvascular density and down-regulation of E-cadherin expression in the tumor should be included among histologic hallmarks of metastatic potential. the role of pregnancy in the aggressive behavior of this tumor is discussed along with a literature review.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Bone Neoplasms / secondary. Lung Neoplasms / secondary. Pregnancy Complications, Neoplastic / pathology. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17178705.001).
  • [ISSN] 1109-3099
  • [Journal-full-title] Hormones (Athens, Greece)
  • [ISO-abbreviation] Hormones (Athens)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Cadherins
  • [Number-of-references] 47
  •  go-up   go-down


44. Karacetin D, Yalcin B, Okten B, Ozturk S, Maral O, Incekara O: Capecitabine and oxaliplatin (XELOX) as first-line treatment for patients with metastatic colorectal cancer. J BUON; 2009 Oct-Dec;14(4):605-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Capecitabine and oxaliplatin (XELOX) as first-line treatment for patients with metastatic colorectal cancer.
  • These drugs have been found to act synergistically, both in vivo and in vitro and their combination (XELOX) is highly active in metastatic colorectal cancer (mCRC).
  • Patient selection criteria included histological confirmation of mCRC, ECOG performance status (PS) <or=2, and adequate bone marrow, renal and hepatic function.
  • Metastatic sites were the liver (23/34; 67%), lung (7/34; 20%), and bone (4/34; 11%).
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Colorectal Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Lung Neoplasms / drug therapy


45. Myrehaug S, Bezjak A: Rapidly progressive bone destruction of the finger as first presentation of systemic metastases from lung cancer. BMJ Case Rep; 2010;2010

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapidly progressive bone destruction of the finger as first presentation of systemic metastases from lung cancer.
  • We report a case of a man with locally advanced lung adenocarcinoma and no evidence of metastatic disease presenting with rapid onset pain and swelling of his right second finger.
  • He clinically worsened, and upon biopsy was found to have metastatic adenocarcinoma of the digit.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22242077.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3029992
  •  go-up   go-down


46. Saif MW, Galanina N, Ravage-Mass L, Kaley K, Cornfeld D, Lamb L, Chhieng D: Bone Metastasis as the Only Metastatic Site in a Patient with Pancreatic Cancer following Distal Pancreatectomy. Case Rep Med; 2010;2010

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone Metastasis as the Only Metastatic Site in a Patient with Pancreatic Cancer following Distal Pancreatectomy.
  • Other less common sites are the lung, brain, kidney, and bone.
  • Here, we report an interesting case of pancreatic adenocarcinoma with exclusive bone metastases and discuss briefly the possible pathogenesis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20862374.001).
  • [ISSN] 1687-9635
  • [Journal-full-title] Case reports in medicine
  • [ISO-abbreviation] Case Rep Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2938458
  •  go-up   go-down


47. Cho JY, Paik YH, Chang YS, Lee SJ, Lee DK, Song SY, Chung JB, Park MS, Yu JS, Yoon DS: Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma. Cancer; 2005 Dec 15;104(12):2753-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma.
  • A Phase II trial was conducted to study a combination of oral capecitabine and gemcitabine (CapGem) as first-line therapy in patients with advanced and/or metastatic biliary carcinoma.
  • METHODS: Patients with unresectable or metastatic intrahepatic or extrahepatic biliary duct carcinoma and gallbladder carcinoma were enrolled.
  • Eligible patients had histologically or cytologically confirmed, measurable adenocarcinoma and had not received prior therapy with capecitabine or gemcitabine.
  • CONCLUSIONS: CapGem is an active and well tolerated first-line combination chemotherapy regimen for patients with advanced/metastatic biliary tract carcinoma that offers a convenient home-based therapy.
  • [MeSH-minor] Adult. Aged. Biopsy, Needle. Bone Neoplasms / secondary. Capecitabine. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Fluorouracil / analogs & derivatives. Humans. Immunohistochemistry. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Prognosis. Risk Assessment. Survival Analysis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 16294346.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


48. Jakhar SL, Dana R, Punia DP: Cancer lung: An unusual presentation. Indian J Med Paediatr Oncol; 2009 Oct;30(4):149-50

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer lung: An unusual presentation.
  • Phalanx bone metastasis as the initial manifestation of lung cancer is a rare presentation.
  • Fine needle aspiration cytology of the swelling suggested a metastatic adenocarcinoma.
  • A skeletal survey, hematological, biochemical, and other radiological tests were found to be normal, except for an opacity seen in the right lung midzone.
  • A bronchoscopic biopsy revealed adenocarcinoma of the lung.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20838560.001).
  • [ISSN] 0975-2129
  • [Journal-full-title] Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology
  • [ISO-abbreviation] Indian J Med Paediatr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2930306
  • [Keywords] NOTNLM ; Bone metastasis / cancer lung / phalanx
  •  go-up   go-down


49. Delgado-López PD, Martín-Velasco V, Castilla-Díez JM, Fernández-Arconada O, Corrales-García EM, Galacho-Harnero A, Rodríguez-Salazar A, Pérez-Mies B: Metastatic meningioma to the eleventh dorsal vertebral body: total en bloc spondylectomy. Case report and review of the literature. Neurocirugia (Astur); 2006 Jun;17(3):240-9
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic meningioma to the eleventh dorsal vertebral body: total en bloc spondylectomy. Case report and review of the literature.
  • Lung and intraabdominal organs are most frequently affected.
  • To our knowledge, this is the first description of a total en bloc spondylectomy through a posterior approach for the treatment of an intraosseous metastatic meningioma to the eleventh dorsal vertebra.
  • The pathological specimen was identified as adenocarcinoma and he initiated chemotherapy.
  • Advice from a second pathologist was seeked, who suggested the diagnosis of intraosseous meningioma.
  • In May 2004 the patient was admitted to our department and a new transpedicular biopsy confirmed the diagnosis.
  • In June 2004 he underwent T11 total en bloc spondylectomy (Tomita's procedure), fusion with bone and calcium substitute-filled stackable carbon-fiber cages, and T9 to L1 transpedicular screw fixation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16855782.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


50. Choi HR, Lee PB, Kim KH: Scapuloplasty alleviates scapular pain resulting from lung cancer metastasis. Pain Physician; 2010 Sep-Oct;13(5):485-91
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Scapuloplasty alleviates scapular pain resulting from lung cancer metastasis.
  • Osteoplasty, a highly effective minimally invasive procedure that alleviates the painful effects of metastatic bone disease by injecting bone cement to support weakened bones, provides immediate and substantial pain relief.
  • According to the reported incidences of operative treatment of different scapula fracture types, 99% of all isolated scapula body fractures are treated nonoperatively A 54-year-old man had been experiencing metastatic bone pain in the lateral border, medial border, and medial infraspinatus fossa of the left scapula for the past 2 months; this pain originated from adenocarcinoma of the right lung.
  • Three 13-gauge, 10-cm long bone biopsy needles were simultaneously inserted from the 3 different entry points to fill the osteolytic lesion with the bone cement with fluoroscopic guidance under local anesthesia and intravenous analgesia.
  • Scapuloplasty is a new variant of osteoplasty used to alleviate the painful effects of metastatic bone disease.
  • [MeSH-major] Adenocarcinoma / secondary. Bone Cements / therapeutic use. Bone Neoplasms / secondary. Lung Neoplasms / pathology. Orthopedic Procedures / methods. Scapula / surgery
  • [MeSH-minor] Fractures, Bone / surgery. Humans. Male. Middle Aged. Minimally Invasive Surgical Procedures / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20859318.001).
  • [ISSN] 2150-1149
  • [Journal-full-title] Pain physician
  • [ISO-abbreviation] Pain Physician
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bone Cements
  •  go-up   go-down


51. Otsuka S, Hanibuchi M, Ikuta K, Yano S, Goto H, Ogino H, Yamada T, Kakiuchi S, Nishioka Y, Takahashi T, Sone S: A bone metastasis model with osteolytic and osteoblastic properties of human lung cancer ACC-LC-319/bone2 in natural killer cell-depleted severe combined immunodeficient mice. Oncol Res; 2009;17(11-12):581-91
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A bone metastasis model with osteolytic and osteoblastic properties of human lung cancer ACC-LC-319/bone2 in natural killer cell-depleted severe combined immunodeficient mice.
  • Lung cancer is commonly associated with multiple-organ metastasis, and bone is a frequent metastatic site for lung cancer.
  • Lung cancer frequently develops osteolytic, and less frequently osteoblastic, metastasis to bone.
  • Osteolytic metastasis models of lung cancer have been reported, but no osteoblastic metastasis model is available for lung cancer.
  • In the present study, we established a reproducible model of human lung cancer with both osteolytic and osteoblastic changes in natural killer cell-depleted severe combined immunodeficient mice.
  • Intravenous inoculation of ACC-LC-319/bone2 cells resulted in the development of metastatic colonies in the lung, liver, and bone of the mice.
  • As assessed sequentially by X-ray photographs, osteolytic bone lesions were observed by day 28, and then osteoblastic lesions were detected by day 35.
  • Histological examination revealed the presence of bony spurs, a hallmark of osteoblastic bone metastasis, where osteoclasts were hardly observed.
  • Treatment with an anti-human vascular endothelial growth factor antibody, bevacizumab, as well as zoledronate, inhibited the number of experimental bone metastases, including osteoblastic changes produced by ACC-LC-319/bone2 cells.
  • These results indicate that our bone metastasis model by ACC-LC319/bone2 might be useful to understand the molecular pathogenesis of osteolytic and osteoblastic metastasis, and to identify molecular targets to control bone metastasis of lung cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Bone Neoplasms / secondary. Lung Neoplasms / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19806789.001).
  • [ISSN] 0965-0407
  • [Journal-full-title] Oncology research
  • [ISO-abbreviation] Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Diphosphonates; 0 / Endothelin-1; 0 / Imidazoles; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab; 6XC1PAD3KF / zoledronic acid
  •  go-up   go-down


52. Baur M, van Oosterom AT, Diéras V, Tubiana-Hulin M, Coombes RC, Hatschek T, Murawsky M, Klink-Alakl M, Hudec M, Dittrich C: A phase II trial of docetaxel (Taxotere) as second-line chemotherapy in patients with metastatic breast cancer. J Cancer Res Clin Oncol; 2008 Feb;134(2):125-35
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of docetaxel (Taxotere) as second-line chemotherapy in patients with metastatic breast cancer.
  • The efficacy and tolerability of docetaxel 100 mg/m(2) every 3 weeks as second-line chemotherapy in patients with metastatic breast cancer was investigated.
  • In conclusion, docetaxel represents one of the most active agents for second-line treatment of metastatic breast cancer, especially for anthracycline-resistant patients.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adolescent. Adult. Aged. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Chemotherapy, Adjuvant. Cohort Studies. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Pharmacol. 1997;39(6):557-60 [9118471.001]
  • [Cites] Eur J Cancer. 1999 Aug;35(8):1194-201 [10615229.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2341-54 [10561296.001]
  • [Cites] Ann Oncol. 1996 Feb;7(2):165-71 [8777173.001]
  • [Cites] Br J Cancer. 1996 Aug;74(4):650-6 [8761385.001]
  • [Cites] Br J Cancer. 2002 Nov 18;87(11):1210-5 [12439707.001]
  • [Cites] J Clin Oncol. 1995 Dec;13(12):2879-85 [8523050.001]
  • [Cites] Breast Cancer Res. 2004;6(5):R601-7 [15318941.001]
  • [Cites] Oncology. 2001;60(1):60-5 [11150910.001]
  • [Cites] N Engl J Med. 2005 Jun 2;352(22):2302-13 [15930421.001]
  • [Cites] J Clin Oncol. 1997 Sep;15(9):3149-55 [9294478.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1169-77 [15718313.001]
  • [Cites] Int J Cancer. 2003 Mar 10;104(1):121-9 [12532428.001]
  • [Cites] Breast Cancer. 2005;12(1):11-5 [15657517.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):562-73 [10653871.001]
  • [Cites] Semin Oncol. 1997 Aug;24(4 Suppl 13):S13-11-S13-18 [9335512.001]
  • [Cites] J Clin Oncol. 2004 Jul 1;22(13):2587-93 [15226326.001]
  • [Cites] J Clin Oncol. 2003 Nov 15;21(22):4165-74 [14559892.001]
  • [Cites] Ann Oncol. 1999 Feb;10(2):205-10 [10093690.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):58-65 [8558221.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):422-31 [15659489.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4927-30 [15256465.001]
  • [Cites] J Clin Oncol. 2000 Dec 1;18(23):3936-45 [11099323.001]
  • [Cites] Ann Oncol. 1993 Aug;4(7):610-1 [8103352.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):968-75 [12637459.001]
  • [Cites] J Cancer Res Clin Oncol. 1987;113(5):488-94 [3624302.001]
  • [Cites] Eur J Cancer. 1995;31A Suppl 4:S11-3 [7577098.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;44(3):253-8 [10453728.001]
  • [Cites] J Clin Oncol. 2002 Jun 15;20(12):2812-23 [12065558.001]
  • [Cites] Br J Clin Pharmacol. 1997 Jun;43(6):653-8 [9205828.001]
  • [Cites] Br J Cancer. 2000 Feb;82(3):529-34 [10682660.001]
  • [Cites] Ann Oncol. 2001 Oct;12(10):1393-8 [11762809.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1413-24 [10334526.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):336-42 [11208824.001]
  • [Cites] Semin Oncol. 1999 Jun;26(3 Suppl 8):21-6 [10403470.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2992-7 [12912947.001]
  • [Cites] Ann Oncol. 2003 Mar;14(3):433-40 [12598350.001]
  • (PMID = 17636328.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Taxoids; 15H5577CQD / docetaxel
  •  go-up   go-down


53. Idelevich E, Karminsky N, Dinerman M, Katsenelson RL, Zvi NB, Baruch NB, Biran H, Man S, Shani A: Phase II study of cisplatin, epirubicin, UFT, and leucovorin (PELUF) as first-line chemotherapy in metastatic gastric cancer. Acta Oncol; 2007;46(3):324-9
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of cisplatin, epirubicin, UFT, and leucovorin (PELUF) as first-line chemotherapy in metastatic gastric cancer.
  • More than two-thirds of patients with gastric cancer present with metastatic disease and their curative options are limited.
  • This phase II study assessed the efficacy and tolerability of cisplatin, epirubicin, tegafur-uracil (UFT) and leucovorin in patients with metastatic gastric cancer (MGC).
  • Thirty-nine patients with previously untreated metastatic or unresectable gastric cancer received intravenous cisplatin 60 mg/m2 and epirubicin 50 mg/m2 on day 1 of a 28-day cycle; UFT 300 mg/m2 was administered with oral leucovorin 30 mg/day in divided doses on days 1-22, followed by a 7-day rest.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Bone Neoplasms / secondary. Cisplatin / administration & dosage. Dose-Response Relationship, Drug. Drug Administration Schedule. Epirubicin / administration & dosage. Female. Follow-Up Studies. Humans. Leucovorin / administration & dosage. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Peritoneal Neoplasms / secondary. Survival Analysis. Tegafur / administration & dosage. Time Factors. Treatment Outcome. Uracil / administration & dosage

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17450467.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 3Z8479ZZ5X / Epirubicin; 56HH86ZVCT / Uracil; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin
  •  go-up   go-down


54. Lasithiotakis K, Petrakis I, Georgiadis G, Paraskakis S, Chalkiadakis G, Chrysos E: Pancreatic resection for metastasis to the pancreas from colon and lung cancer, and osteosarcoma. JOP; 2010;11(6):593-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic resection for metastasis to the pancreas from colon and lung cancer, and osteosarcoma.
  • CONTEXT: Pancreatic resection for a metastatic colon, lung cancer or an osteosarcoma has rarely been reported in the literature and there is controversy regarding recurrence and the overall survival of these patients.
  • We herein evaluate the outcome of three patients who underwent pancreaticoduodenectomy for the aforementioned metastatic tumors to the pancreas.
  • All the pancreatic lesions were located in the head of the pancreas, and the intervals between the diagnosis of the primary cancer and the pancreatic metastases were 6, 14 and 24 months.
  • During exploration of the abdomen, additional metastatic lesions in the small intestine and liver were detected and resected in two patients.
  • CONCLUSION: Pancreatic resection for metastatic disease may be suggested for selected patients, even those with limited extrapancreatic disease.
  • [MeSH-major] Bone Neoplasms / pathology. Colonic Neoplasms / pathology. Lung Neoplasms / pathology. Osteosarcoma / pathology. Pancreatic Neoplasms / secondary. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adolescent. Female. Humans. Male. Middle Aged. Pancreatectomy / methods


55. Chiesa MD, Buti S, Tomasello G, Negri F, Buononato M, Brunelli A, Lazzarelli S, Brighenti M, Donati G, Passalacqua R: A pilot phase II study of chemotherapy with oxaliplatin, folinic acid, 5-fluorouracil and irinotecan in metastatic gastric cancer. Tumori; 2007 May-Jun;93(3):244-7
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pilot phase II study of chemotherapy with oxaliplatin, folinic acid, 5-fluorouracil and irinotecan in metastatic gastric cancer.
  • AIMS AND BACKGROUND: Previous phase II studies have reported that combinations of oxaliplatin, folinic acid and 5-fluorouracil or irinotecan, folinic acid and 5-fluorouracil are associated with good efficacy and an acceptable safety profile in metastatic gastric cancer.
  • The aim of this study was to evaluate chemotherapy with oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI regimen) in metastatic gastric cancer.
  • RESULTS: Seventeen patients with metastatic gastric cancer were enrolled.
  • [MeSH-major] Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Anemia / chemically induced. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Camptothecin / administration & dosage. Camptothecin / adverse effects. Camptothecin / analogs & derivatives. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Gastrointestinal Diseases / chemically induced. Humans. Leucovorin / administration & dosage. Leucovorin / adverse effects. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neutropenia / chemically induced. Organoplatinum Compounds / administration & dosage. Organoplatinum Compounds / adverse effects. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary. Pilot Projects. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17679458.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


56. Kreusel KM, Bechrakis NE, Wiegel T, Krause L, Foerster MH: Incidence and clinical characteristics of symptomatic choroidal metastasis from lung cancer. Acta Ophthalmol; 2008 Aug;86(5):515-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and clinical characteristics of symptomatic choroidal metastasis from lung cancer.
  • PURPOSE: To determine the clinical characteristics of symptomatic choroidal metastasis (CM) resulting from metastatic lung cancer.
  • METHODS: Twenty-two consecutive patients with symptomatic CM resulting from lung cancer were retrospectively reviewed for ocular findings, medical history and systemic disease.
  • All patients underwent a complete screening for further organ metastasis by computed tomography (CT) and bone scintigraphy.
  • RESULTS: In eight of 22 (36%; 95% confidence interval [CI] 17-59) patients, lung cancer had been diagnosed before occurrence of CM, with a median interval of 13 months.
  • In 14 patients lung cancer was detected after diagnosis of CM, with a median interval of 1 month.
  • Median survival after diagnosis of symptomatic CM was 13 months, by contrast with 2 months in lung cancer patients with CM identified in an ocular screening study.
  • CONCLUSIONS: Symptomatic choroidal lung cancer metastasis in the majority of patients presents as a solitary tumour before diagnosis of lung cancer in patients with multiple organ systems affected by metastatic disease.
  • [MeSH-major] Choroid Neoplasms / secondary. Lung Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / epidemiology. Adenocarcinoma / secondary. Adult. Aged. Carcinoid Tumor / diagnosis. Carcinoid Tumor / epidemiology. Carcinoid Tumor / secondary. Carcinoma, Large Cell / diagnosis. Carcinoma, Large Cell / epidemiology. Carcinoma, Large Cell / secondary. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / secondary. Female. Humans. Incidence. Male. Middle Aged. Positron-Emission Tomography. Retrospective Studies. Small Cell Lung Carcinoma / diagnosis. Small Cell Lung Carcinoma / epidemiology. Small Cell Lung Carcinoma / secondary. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18081901.001).
  • [ISSN] 1755-3768
  • [Journal-full-title] Acta ophthalmologica
  • [ISO-abbreviation] Acta Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


57. El-Rayes BF, Zalupski M, Bekai-Saab T, Heilbrun LK, Hammad N, Patel B, Urba S, Shields AF, Vaishampayan U, Dawson S, Almhanna K, Smith D, Philip PA: A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. Ann Oncol; 2010 Oct;21(10):1999-2004
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers.
  • This phase II study was undertaken to determine the effects of adding bevacizumab to a regimen of docetaxel and oxaliplatin in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction.
  • PATIENTS AND METHODS: Previously untreated patients with locally advanced or metastatic disease and a performance status (PS) of 0-1 were eligible for this study.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Lancet Oncol. 2009 Jun;10(6):559-68 [19482548.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] Cancer Metastasis Rev. 1990 Nov;9(3):171-4 [1705485.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):261-7 [8996151.001]
  • [Cites] Pathol Int. 1998 Jul;48(7):499-506 [9701011.001]
  • [Cites] Int J Cancer. 1998 Sep 11;77(6):933-6 [9714067.001]
  • [Cites] Clin Cancer Res. 1996 Oct;2(10):1679-84 [9816116.001]
  • [Cites] Langenbecks Arch Surg. 1999 Jun;384(3):264-70 [10437615.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] J Clin Oncol. 2006 May 10;24(14):2137-50 [16682732.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):4991-7 [17075117.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5201-6 [17114652.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] Nat Rev Drug Discov. 2007 Apr;6(4):273-86 [17396134.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1539-44 [17442997.001]
  • [Cites] Ann Oncol. 2007 Dec;18(12):2006-8 [17951596.001]
  • [Cites] N Engl J Med. 2007 Dec 27;357(26):2666-76 [18160686.001]
  • [Cites] Ann Oncol. 2008 Jan;19(1):104-8 [17897959.001]
  • [Cites] N Engl J Med. 2008 Jan 3;358(1):36-46 [18172173.001]
  • [Cites] Br J Cancer. 2008 Feb 12;98(3):542-6 [18212754.001]
  • [Cites] Anticancer Drugs. 2008 Jun;19(5):535-9 [18418220.001]
  • [Cites] J Clin Oncol. 2008 Nov 20;26(33):5326-34 [18854571.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Jul;64(2):347-53 [19066894.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • (PMID = 20332133.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-22453
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Organoplatinum Compounds; 0 / Taxoids; 04ZR38536J / oxaliplatin; 15H5577CQD / docetaxel; 2S9ZZM9Q9V / Bevacizumab
  • [Other-IDs] NLM/ PMC2980934
  •  go-up   go-down


58. Ramkumar U, Munshi NI, El-Jabbour JN: Occult carcinoma of the lung presenting as pain in the hallux: a case report. J Foot Ankle Surg; 2005 Nov-Dec;44(6):483-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occult carcinoma of the lung presenting as pain in the hallux: a case report.
  • Metastatic tumors to the hands and feet (acrometastases) are rare.
  • We report a case in which the primary presentation of a lung carcinoma was a metastatic lesion to the distal phalanx of the hallux.
  • Radiographs and computed tomography suggested a benign lesion in the distal phalanx of the hallux, but curettage and biopsy revealed metastatic adenocarcinoma.
  • A chest x-ray revealed a mass in the right perihilar region, which was confirmed by CT, bronchoscopy, and biopsy as carcinoma of the lung.
  • A review of the literature reveals that there is a tendency toward delayed diagnosis in similar cases, especially when the primary lesion is asymptomatic.
  • A high index of suspicion is needed for early diagnosis in such cases.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Bone Neoplasms / secondary. Hallux / pathology. Lung Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16257681.001).
  • [ISSN] 1067-2516
  • [Journal-full-title] The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons
  • [ISO-abbreviation] J Foot Ankle Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Omuro AM, Kris MG, Miller VA, Franceschi E, Shah N, Milton DT, Abrey LE: High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer; 2005 Jun 1;103(11):2344-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib.
  • BACKGROUND: Gefitinib is an epidermal growth factor receptor tyrosine kinase inhibitor that induces an early and dramatic response in 10% of patients with advanced nonsmall cell lung carcinoma (NSCLC).
  • All responders had adenocarcinoma.
  • In 9 (43%) patients, the initial site of disease recurrence was the lung and in 1 it was the liver and bone.
  • Four (57%) of the patients with disease recurrence in the CNS had lung disease under control.
  • Intrinsic resistance of metastatic clones, incomplete CNS penetrance of the drug, and longer survival are possible explanations for this high incidence.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / secondary. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms / drug therapy. Meningeal Neoplasms / secondary. Quinazolines / therapeutic use

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15844174.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


60. Gontier E, Vaylet F, Bonardel G, Mantzarides M, Salles Y, Guigay J, Foehrenbach H, L'Her P: [18-FDG positon emission tomography and distal metastasis from lung cancer]. Rev Pneumol Clin; 2005 Sep;61(4 Pt 1):248-57
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [18-FDG positon emission tomography and distal metastasis from lung cancer].
  • We report the cases of three patients with non-small-cell lung cancer who developed secondary distal localizations beyond the acquisition field of "whole body" FDG-PET.
  • Lung cancer is known to favor hematogenic dissemination, raising the possibility of early distal metastasis.
  • Furthermore, the diagnostic yield of this type of examination may be low since it can be estimated that about 1% of patients will develop isolated distal metastases (3 out of 293 patients in our series initially treated for non-metastatic non-small-cell lung cancer).
  • In the current context of technical availability, systematic inclusion of the lower limbs in the PET scan acquisition field would not appear warranted for the initial work-up of patients with non-small-cell lung cancer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Fluorodeoxyglucose F18. Lung Neoplasms / pathology. Positron-Emission Tomography. Radiopharmaceuticals. Whole Body Imaging
  • [MeSH-minor] Adenocarcinoma / secondary. Aged. Aged, 80 and over. Bone Neoplasms / secondary. Carcinoma, Squamous Cell / secondary. Female. Femur / pathology. Humans. Male. Middle Aged. Muscle Neoplasms / secondary. Retrospective Studies. Tibia / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16208188.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


61. Noguchi T, Nakayama E, Yasuda J, Terada Y: [A case of meningeal carcinomatosis from lung cancer successfully treated with aggressive multimodal therapy]. Nihon Kokyuki Gakkai Zasshi; 2007 Mar;45(3):267-71
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of meningeal carcinomatosis from lung cancer successfully treated with aggressive multimodal therapy].
  • A 44-year-old man was admitted to our hospital because of brain metastasis and intrapulmonary exacerbation of lung adenocarcinoma.
  • Whole-brain and whole-marrow radiation along with systemic chemotherapy gave a marked improvement in the symptoms and in the metastatic shadow on the chest CT scan.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow / radiation effects. Cranial Irradiation. Lung Neoplasms / pathology. Meningeal Neoplasms / drug therapy. Meningeal Neoplasms / secondary

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17419441.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


62. Lu S, Zhang J, Zhou Z, Liao ML, He WZ, Zhou XY, Li ZM, Xiang JQ, Wang JJ, Chen HQ: Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice. Oncol Rep; 2008 Sep;20(3):581-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.
  • However, there is limited data on the effects of combination therapies on the development of bone metastasis in animal models of lung cancer.
  • The purpose of this study was to establish a human lung adenocarcinoma cell line with high bone metastatic potential in an immunodeficient mouse model and to evaluate the synergistic inhibitory activity of zoledronate and paclitaxel (P) on bone metastasis in nude mice.
  • A human lung adenocarcinoma cell line with high bone metastatic potential (SPC-A1-BM) was established by 10 rounds of in vivo selection.
  • Tumor growth was evaluated with bone scans, X-rays and in situ immunohistochemistry.
  • Bone scan, radiographic and histological assessments revealed fewer bone metastases in all treatment groups vs. vehicle, with P + ZOL significantly reducing the incidence of bone metastases detected by bone scans (P=0.020) and X-rays (P=0.036).
  • A histological analysis revealed marginal differences in the number of bone metastases between P + ZOL and vehicle (P=0.058).
  • Compared with vehicle and ZOL alone, cancerous cells in the bone of mice treated with P + ZOL expressed higher levels of Bax and lower levels of Bcl-2 and Bcl-xl.
  • The results of this study indicated that zoledronate enhanced the efficacy of paclitaxel synergistically, by reducing the incidence of bone metastasis from lung cancer and prolonging survival in a mouse model of non-small cell lung cancer with a high potential for metastasis to bone.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Bone Density Conservation Agents / therapeutic use. Bone Neoplasms / drug therapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Diphosphonates / therapeutic use. Imidazoles / therapeutic use. Paclitaxel / therapeutic use
  • [MeSH-minor] Animals. Collagen Type I / blood. Drug Therapy, Combination. Enzyme-Linked Immunosorbent Assay. Humans. Immunoenzyme Techniques. Incidence. Lung Neoplasms / drug therapy. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Mice. Mice, Nude. Peptides / blood. Proto-Oncogene Proteins c-bcl-2 / metabolism. Survival Rate. Tumor Cells, Cultured. Xenograft Model Antitumor Assays. bcl-2-Associated X Protein / metabolism. bcl-X Protein / metabolism

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18695909.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Bcl2l1 protein, mouse; 0 / Bone Density Conservation Agents; 0 / Collagen Type I; 0 / Diphosphonates; 0 / Imidazoles; 0 / Peptides; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-2-Associated X Protein; 0 / bcl-X Protein; 0 / collagen type I trimeric cross-linked peptide; 6XC1PAD3KF / zoledronic acid; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


63. Miyazaki T, Tagawa T, Nakamura A, Yamasaki N, Hashizume S, Matsumoto K, Taguchi T, Morino S, Nagayasu T: [Surgical treatment for stage IV lung cancer]. Kyobu Geka; 2006 Jan;59(1):36-40
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment for stage IV lung cancer].
  • OBJECTIVE: To find out the optimal surgical indication in stage IV lung cancer patients, we evaluated them retrospectively.
  • The most common histological type was adenocarcinoma (67.7%).
  • The metastatic lesions were lung (33.9%), brain (24.2%), liver, bone, adrenal gland and so on.
  • The overall survival rate of stage IV lung cancer was 10.4% at 5-year.
  • Five-year survival for patients with lung or brain metastasis who had no lymph node metastasis were significantly more superior than those with lymph node metastasis (p=0.0389, 0.0021).
  • Two were lung and the others were brain and adrenal gland metastasis without lymph node metastasis.
  • CONCLUSION: Stage IV lung cancer with lung or brain or adrenal gland metastasis without lymph node metastasis should be resected.
  • [MeSH-major] Lung Neoplasms / pathology. Lung Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Brain Neoplasms / mortality. Brain Neoplasms / secondary. Female. Humans. Male. Middle Aged. Neoplasm Staging / mortality. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16440683.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


64. Destombe C, Botton E, Le Gal G, Roudaut A, Jousse-Joulin S, Devauchelle-Pensec V, Saraux A: Investigations for bone metastasis from an unknown primary. Joint Bone Spine; 2007 Jan;74(1):85-9
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Investigations for bone metastasis from an unknown primary.
  • OBJECTIVES: To evaluate the respective contributions of various investigations used to identify the primary tumor in a cohort of patients referred for diagnostic evaluation of one or more bone metastases.
  • METHODS: A single-center retrospective study was conducted in a cohort of patients admitted between October 1990 and January 2000 for evaluation of one or more bone metastases with no known primary.
  • All patients underwent radionuclide bone scanning, a chest radiograph, and an abdominal ultrasound scan.
  • Using the final diagnosis as the reference standard, we evaluated the diagnostic usefulness of each investigation.
  • The primary was located in the lung in 37 patients, prostate in 26, breast or female genital tract in 24, urinary system in 11, gastrointestinal tract in 11, head and neck in 6, and other organs in 4.
  • The extraskeletal metastases were located chiefly in the liver (20.4%), lung (17.1%), pleura (13.2%), and brain (7.2%).
  • Bone biopsies were performed in 107 patients: 84 had a single bone biopsy, 16 had two bone biopsies, and 7 had three bone biopsies.
  • The first bone biopsy was taken in the rheumatology department with or without fluoroscopic guidance in 62 patients, in the radiology department under CT guidance in 6 patients, and in the surgery department in 32 patients; this information was unavailable for the 7 remaining patients.
  • The first bone biopsy was taken from the iliac bone in 48 patients, spine in 32, sacrum in 10, rib in 3, and other sites in 7.
  • The histological biopsy findings indicated adenocarcinoma in 58 cases, epidermoid carcinoma in 28 cases, undifferentiated carcinoma in 2 cases, and other histological patterns in 9 cases.
  • In 80 patients, another metastatic site was easier to access than the bone metastasis.
  • CONCLUSION: Bone biopsies performed by rheumatologists, generally under fluoroscopic guidance, usually indicate the site of the primary or at least the histological type.
  • [MeSH-major] Bone Neoplasms / diagnosis. Bone Neoplasms / secondary. Neoplasms, Unknown Primary / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor. Biopsy. Bone and Bones / pathology. Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Cohort Studies. Diagnostic Imaging. Female. Humans. Lung Neoplasms / diagnosis. Lung Neoplasms / pathology. Male. Middle Aged. Retrospective Studies. Sensitivity and Specificity. Urogenital Neoplasms / diagnosis. Urogenital Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Joint Bone Spine. 2008 Jan;75(1):100; author reply 100-1 [18083617.001]
  • (PMID = 17218141.001).
  • [ISSN] 1778-7254
  • [Journal-full-title] Joint, bone, spine : revue du rhumatisme
  • [ISO-abbreviation] Joint Bone Spine
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


65. Mitsuhashi T, Shimizu Y, Ban S, Ogawa F, Hirose T, Tanaka J, Shimizu M: Multicentric contiguous variant of epithelioid angiosarcoma of the bone. A rare variant showing angiotropic spread. Ann Diagn Pathol; 2005 Feb;9(1):33-7
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentric contiguous variant of epithelioid angiosarcoma of the bone. A rare variant showing angiotropic spread.
  • Epithelioid angiosarcoma of the bone is a rare tumor and is a diagnostic challenge.
  • The initial diagnosis of a tibial biopsy was poorly differentiated adenocarcinoma.
  • On the occasion of autopsy, a fungating thrombotic nodule was found at the anterior wall of the right atrium, and small hemorrhagic infarcts with tumor thrombi were found in the lung.
  • This case showed angiotropic spread of the tumor only to the right atrium and the lung, with no solid mass in other organs.
  • Multicentric epithelioid angiosarcoma of the bone is a pitfall in pathological diagnoses, especially if a strong radiological impression of metastatic carcinoma is provided.
  • [MeSH-major] Bone Neoplasms / pathology. Epithelioid Cells / pathology. Hemangiosarcoma / secondary. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Adenocarcinoma / diagnosis. Antigens, CD31 / analysis. Biomarkers, Tumor / analysis. Biopsy. Diagnosis, Differential. Fatal Outcome. Humans. Immunohistochemistry. Keratins / analysis. Male. Middle Aged. Neoplasm Invasiveness / pathology. Tibia / pathology. Vimentin / analysis. von Willebrand Factor / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15692948.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Biomarkers, Tumor; 0 / Vimentin; 0 / von Willebrand Factor; 68238-35-7 / Keratins
  •  go-up   go-down


66. Sundermeyer ML, Meropol NJ, Rogatko A, Wang H, Cohen SJ: Changing patterns of bone and brain metastases in patients with colorectal cancer. Clin Colorectal Cancer; 2005 Jul;5(2):108-13
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changing patterns of bone and brain metastases in patients with colorectal cancer.
  • BACKGROUND: Therapeutic advances for patients with metastatic colorectal cancer (CRC) have been associated with prolonged survival.
  • This study was undertaken to test the hypothesis that expanded treatment options and resultant improved survival for patients with metastatic CRC are associated with an increased incidence of metastases at uncommon sites.
  • PATIENTS AND METHODS: Patients with metastatic CRC evaluated from 1993 to 2002 at the Fox Chase Cancer Center were identified.
  • Medical records were abstracted to obtain the following: date of diagnosis/metastasis, primary tumor site, therapeutic agents received, survival, and site(s) of metastases.
  • Incidence of bone and brain metastases were 10.4% (95% CI, 8.6%-12.4%) and 3% (95% CI, 2.2%-4.5%), respectively.
  • Bone metastases were more common with increased numbers of active systemic agents received: 0 (3.7%), 1 (9.4%), 2 (10.9%), 3 (16.3%), and 4/5 (17.4%; P = 0.001; trend test).
  • Patients receiving irinotecan or oxaliplatin were more likely to develop bone metastases (13.2% vs. 8.3%, P = 0.01 for irinotecan; 16.9% vs. 9%, P = 0.003 for oxaliplatin).
  • Patients with primary rectal versus primary colon cancer were more likely to develop bone metastases (16% vs. 8.6%; P = 0.001).
  • Patients with lung metastases were more likely to have bone metastases (16.1% vs. 6.4%; P < 0.0001) or brain metastases (6.2% vs. 1.2%; P < 0.0001) than those without.
  • CONCLUSION: These data demonstrate that the incidence of bone and brain metastases in patients with CRC is more common than previously reported and is associated with receipt of multiple systemic treatments.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma / secondary. Bone Neoplasms / epidemiology. Bone Neoplasms / secondary. Brain Neoplasms / epidemiology. Brain Neoplasms / secondary. Colorectal Neoplasms / pathology


67. Ogawa Y, Sugawara T, Seki H, Sakuma T: Thyroid follicular carcinoma metastasized to the lung, skull, and brain 12 years after initial treatment for thyroid gland--case report. Neurol Med Chir (Tokyo); 2006 Jun;46(6):302-5
Hazardous Substances Data Bank. LEVOTHYROXINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid follicular carcinoma metastasized to the lung, skull, and brain 12 years after initial treatment for thyroid gland--case report.
  • A 65-year-old woman presented with multiple metastases from thyroid follicular carcinoma to the lung, skull, and brain.
  • The lung tumor was treated by conventional irradiation and radioactive ablation.
  • Follicular carcinoma is thought to have the most optimistic prognosis even with metastases to the lymph nodes and lung.
  • Radioactive ablation using iodine-131 is widely used to treat the primary and/or metastatic lesion.
  • Surgical excision of the metastatic intracranial lesion may be the only effective treatment.
  • [MeSH-major] Adenocarcinoma, Follicular / secondary. Brain Neoplasms / secondary. Epidural Neoplasms / secondary. Lung Neoplasms / secondary. Postoperative Complications / pathology. Radiosurgery. Skull Neoplasms / secondary. Thyroid Neoplasms / radiotherapy. Thyroid Neoplasms / surgery
  • [MeSH-minor] Aged. Cerebral Hemorrhage / pathology. Combined Modality Therapy. Female. Humans. Iodine Radioisotopes / therapeutic use. Lung / pathology. Occipital Bone / pathology. Occipital Bone / surgery. Occipital Lobe / pathology. Occipital Lobe / surgery. Parietal Bone / pathology. Parietal Bone / surgery. Thyroidectomy. Thyroxine / administration & dosage

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16794352.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; Q51BO43MG4 / Thyroxine
  •  go-up   go-down


68. Duda DG, Cohen KS, Kozin SV, Perentes JY, Fukumura D, Scadden DT, Jain RK: Evidence for incorporation of bone marrow-derived endothelial cells into perfused blood vessels in tumors. Blood; 2006 Apr 1;107(7):2774-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence for incorporation of bone marrow-derived endothelial cells into perfused blood vessels in tumors.
  • Recent studies have demonstrated that the cellular contribution of the bone marrow to tumor neovascularization is highly complex.
  • In this context, the extent to which bone marrow-derived cells incorporate as bona fide endothelial (nonhematopoietic) cells into perfused tumor vessels, or any new vessels formed postnatally (vasculogenesis), is unclear.
  • To this end, we developed models to characterize local vessel-derived and bone marrow-derived endothelial cells (BMD-ECs).
  • Finally, we quantified their contribution to perfused blood vessels in tumors using transplanted as well as spontaneous primary and metastatic tumor models.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 2000 Jan;105(1):17-9 [10619857.001]
  • [Cites] Nat Cell Biol. 2005 Sep;7(9):870-9 [16113679.001]
  • [Cites] Cell. 2001 May 4;105(3):369-77 [11348593.001]
  • [Cites] Nat Med. 2001 Nov;7(11):1194-201 [11689883.001]
  • [Cites] Nat Med. 2002 Jun;8(6):607-12 [12042812.001]
  • [Cites] Nature. 2002 Jul 4;418(6893):41-9 [12077603.001]
  • [Cites] Science. 2003 May 16;300(5622):1155-9 [12750523.001]
  • [Cites] Nat Med. 2003 Jun;9(6):789-95 [12740570.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):515-6 [12842078.001]
  • [Cites] Cancer Cell. 2003 Oct;4(4):277-89 [14585355.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):763-8 [14718670.001]
  • [Cites] Nat Med. 2004 Sep;10(9):950-8 [15334073.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1769-77 [15187022.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):5920-4 [15342367.001]
  • [Cites] Blood. 2004 Oct 1;104(7):2084-6 [15191949.001]
  • [Cites] Cancer Cell. 2004 Oct;6(4):409-21 [15488763.001]
  • [Cites] Nat Med. 1999 Apr;5(4):434-8 [10202935.001]
  • [Cites] Blood. 2005 Jan 15;105(2):679-81 [15358628.001]
  • [Cites] Cancer Cell. 2005 Jan;7(1):101-11 [15652753.001]
  • [Cites] Nat Med. 2005 Mar;11(3):261-2 [15723071.001]
  • [Cites] J Cell Mol Med. 2005 Jan-Mar;9(1):113-21 [15784169.001]
  • [Cites] Cell. 2005 May 6;121(3):335-48 [15882617.001]
  • [Cites] Nature. 2000 Sep 14;407(6801):249-57 [11001068.001]
  • (PMID = 16339405.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01-CA80124; United States / NCI NIH HHS / CA / R01-CA115767; United States / NCI NIH HHS / CA / R01-CA96915
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  • [Other-IDs] NLM/ PMC1895376
  •  go-up   go-down


69. Ruiz M, Salvador J, Bayo J, Lomas M, Moreno A, Valero M, Bernabé R, Vicente D, Jiménez J, Lopez-Ladrón A: Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer. Cancer Chemother Pharmacol; 2008 Nov;62(6):1085-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer.
  • BACKGROUND: Addition of carboplatin (C) to trastuzumab (T) and paclitaxel (P) improves the efficacy in HER2+ metastatic breast cancer (MBC).
  • RESULTS: Forty-one patients (pts) were enrolled-median age: 54.5 years (range 29-75); 87.8% PS 0 or 1; 39 (97.5%) had received prior adjuvant or neoadjuvant treatment; 11 (27%) had received one prior CT line for metastatic disease; disease sites: liver (40%), bone (32.5%), lymph nodes (32.5%) and lung (20%); 19 (47.5%) had > or =2 lesions and 97.5% had measurable disease.
  • [MeSH-major] Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Genes, erbB-2

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18365200.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; BG3F62OND5 / Carboplatin; P188ANX8CK / Trastuzumab; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


70. Lange T, Müller-Tidow C, Serve H, Hoffknecht P, Berdel WE, Thomas M: First-line systemic treatment with gefitinib in stage IV non-small cell lung cancer. Oncol Rep; 2005 Dec;14(6):1539-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First-line systemic treatment with gefitinib in stage IV non-small cell lung cancer.
  • Lung cancer has a high mortality rate and is often diagnosed in locally advanced or metastatic stages.
  • A new therapeutic option for patients with non-small cell lung cancer (NSCLC) in these stages with progress or relapse after platinum-based chemotherapy exists in the inhibitors of the epidermal growth factor receptor (EGFR) tyrosine-kinase.
  • We present a case of a 53-year-old woman who was diagnosed due to pain from multiple bone metastases of a lung adenocarcinoma.
  • She refused cytotoxic chemotherapy, and we administered first-line systemic treatment with gefitinib subsequent to radiotherapy of metastatic bone disease.
  • EGFR tyrosine-kinase inhibitors (TKI) can be an alternative first-line systemic treatment option for selected patients with metastatic NSCLC.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Base Sequence. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. DNA Mutational Analysis. Female. Humans. Middle Aged. Neoplasm Staging. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptor, Epidermal Growth Factor / genetics. Sequence Deletion. Treatment Outcome


71. Zhang JQ, Huang XQ, Zhang J, Cai P, Chen W, Wang J, Zhou DQ, Zhang EQ: [CT guided radioactive seed (125)I implantation in treating multiple bone metastasis]. Zhonghua Yi Xue Za Zhi; 2008 Oct 28;88(39):2739-42
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [CT guided radioactive seed (125)I implantation in treating multiple bone metastasis].
  • OBJECTIVE: To investigate the clinical value of CT guided radioactive seed (125)I implantation in treating bone metastasis.
  • METHODS: 28 multiple bone metastatic tumor patients with 116 metastatic lesions totally, adenocarcinoma of lung in 6 cases, squamous cell carcinoma of lung, renal clear-cell carcinoma, and carcinoma of prostate in 4 cases each, hepatocellular carcinoma and colon carcinoma in 3 cases each, breast carcinoma in 2 cases, and malignant schwannoma and pancreatic cancer in 1 case each, 13 males and 15 females, aged 49.8, underwent CT guided radioactive seed (125)I implantation into bone metastatic lesions.
  • CONCLUSION: CT guided radioactive seed (125)I implantation procedure has good clinical effects in treating bone metastasis with minimal invasive and few complications.
  • [MeSH-major] Bone Neoplasms / radiotherapy. Brachytherapy / methods. Iodine Radioisotopes / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19080445.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


72. Yang L, Liu XY, Fang J, An TT, Wu MN: [Gefitinib in the treatment of advanced non-small cell lung cancer]. Zhonghua Zhong Liu Za Zhi; 2006 Jun;28(6):474-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gefitinib in the treatment of advanced non-small cell lung cancer].
  • OBJECTIVE: To investigate the efficacy, time to progression, survival time and toxicity of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor Gefitinib (Iressa), a target therapy agent, in the treatment of advanced non-small cell lung cancer (NSCLC), and to analyze the factors affecting the efficacy and patients' survival.
  • The disease control rate of those who had adenocarcinoma, or received second-line chemotherapy or developed skin toxicity was significantly better than the other patients (P value = 0.04, 0.02, 0.00, respectively). (2) Median time to progress (TIP) was 5.0 months (95% CI 3.26-6.74). (3) Median following-up duration was 7.5 months (1-18.
  • Non-smoker, stable diseases, skin toxicities, and controlled metastatic diseases during the treatment of gefitinib were the favorable factors affecting the survival (P value = 0.00, 0.00, 0.00, 0.01, respectively). (4) The main toxicity of gefitinib was grade I or II skin toxicity.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Disease Progression. Exanthema / chemically induced. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17152500.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


73. Tartarone A: Pemetrexed in heavily pretreated non-small-cell lung cancer patients: case report and review of the literature. Future Oncol; 2010 Dec;6(12):1937-40
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pemetrexed in heavily pretreated non-small-cell lung cancer patients: case report and review of the literature.
  • To date, there is no standard treatment for patients with metastatic non-small-cell lung cancer after multiple previous lines of chemotherapy.
  • Pemetrexed in combination with cisplatin or as a single agent demonstrated significant activity in patients with nonsquamous non-small-cell lung cancer with a good toxicity profile.
  • In this article, we present a case of pulmonary adenocarcinoma treated with pemetrexed after five lines of treatment, including the cytotoxic agents cisplatin plus vinorelbine, docetaxel, gemcitabine and the tyrosine kinase inhibitor erlotinib.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Glutamates / therapeutic use. Guanine / analogs & derivatives
  • [MeSH-minor] Bone Neoplasms / drug therapy. Bone Neoplasms / radiotherapy. Bone Neoplasms / secondary. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Brain Neoplasms / secondary. Combined Modality Therapy. Fatal Outcome. Humans. Male. Middle Aged. Neoplasm Staging. Palliative Care. Pemetrexed

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. PEMETREXED .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21142866.001).
  • [ISSN] 1744-8301
  • [Journal-full-title] Future oncology (London, England)
  • [ISO-abbreviation] Future Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine
  •  go-up   go-down


74. Zhong XJ, Li DT, Li XL, Mu DB, Zhang XG, Luo JY: [Comparison of the characteristics in recurrence and metastasis between bronchioloalveolar carcinoma and other lung adenocarcinomas]. Ai Zheng; 2007 Jul;26(7):785-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison of the characteristics in recurrence and metastasis between bronchioloalveolar carcinoma and other lung adenocarcinomas].
  • Although bronchioloalveolar carcinoma is a subtype of lung adenocarcinoma, its biological features are better than those of other lung adenocarcinomas.
  • This study was to analyze differences in metastatic activity between bronchioloalveolar carcinoma and other lung adenocarcinomas.
  • METHODS: The expression of E-Cadherin, Collagen IV, vascular endothelial growth factor receptor-2 (VEGFR-2), matrix metalloproteinase-9 (MMP-9), and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in 28 specimens of stage I bronchioloalveolar carcinoma confirmed pathologically and 40 specimens of other stage I lung adenocarcinomas were detected by immunohistochemistry.
  • RESULTS: The 5-year survival rate was significantly higher in ths patients with bronchioloalveolar carcinoma than in the patients with other lung adenocarcinomas (88.7% vs. 57.3%, P < 0.05).
  • The intrathoracic recurrence rate was significantly higher and the extrathoracic metastasis rate was significantly lower in the patients with bronchioloalveolar carcinoma than in the patients with other lung adenocarcinomas (75% vs. 33.3%, 25% vs. 66.7%, P < 0.05).
  • The positive rates of Collagen IV, E-Cadherin and TIMP-1 were significantly higher in bronchioloalveolar carcinoma than in other lung adenocarcinomas (78.6% vs. 42.5%, 78.6% vs. 40.0%, 67.5% vs. 42.9%, all P < 0.01).
  • The positive rate of VEGFR-2 was significantly higher in other lung adenocarcinomas than in bronchioloalveolar carcinoma (85.7% vs. 77.5%, P < 0.05).
  • There was no significant difference in the positive rate of MMP-9 between bronchioloalveolar carcinoma and other lung adenocarcinomas (85.0% vs. 78.6%, P = 0.494).
  • CONCLUSION: As compared with other lung adenocarcinomas, stage I bronchioloalveolar carcinoma is less aggressive in clinical behavior and likely to develop intrathoracic recurrence, with less extrathoracic metastases and better prognosis.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Collagen Type IV / metabolism. Lung Neoplasms / pathology. Neoplasm Recurrence, Local
  • [MeSH-minor] Bone Neoplasms / secondary. Brain Neoplasms / secondary. Cadherins / metabolism. Female. Follow-Up Studies. Humans. Male. Matrix Metalloproteinase 9 / metabolism. Middle Aged. Neoplasm Staging. Survival Rate. Tissue Inhibitor of Metalloproteinase-1 / metabolism. Vascular Endothelial Growth Factor Receptor-2 / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17626761.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cadherins; 0 / Collagen Type IV; 0 / Tissue Inhibitor of Metalloproteinase-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


75. Yano T, Haro A, Yoshida T, Morodomi Y, Ito K, Shikada Y, Shoji F, Maruyama R, Maehara Y: Prognostic impact of local treatment against postoperative oligometastases in non-small cell lung cancer. J Surg Oncol; 2010 Dec 1;102(7):852-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic impact of local treatment against postoperative oligometastases in non-small cell lung cancer.
  • OBJECTIVES: In this study, we investigated prognostic factors associated with survival after distantly metastatic recurrence in surgically resected non-small cell lung cancer (NSCLC), and clarified the influence of local treatment on the prognosis for oligometastatic recurrence.
  • The targeted metastatic organs were brain in 14 patients, bone in 14, lungs in 12, and other organs in 4.
  • Significant prognostic factors for postrecurrence survival included adenocarcinoma histology, long disease-free interval (DFI) (1 year or longer), and the performance of local treatment for oligometastases.
  • [MeSH-major] Bone Neoplasms / surgery. Brain Neoplasms / surgery. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery. Neoplasm Recurrence, Local / surgery


76. Fujie S, Okumura Y, Sato S, Akaki S, Katsui K, Himei K, Takemoto M, Kanazawa S: Diagnostic capabilities of I-131, TI-201, and Tc-99m-MIBI scintigraphy for metastatic differentiated thyroid carcinoma after total thyroidectomy. Acta Med Okayama; 2005 Jun;59(3):99-107
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic capabilities of I-131, TI-201, and Tc-99m-MIBI scintigraphy for metastatic differentiated thyroid carcinoma after total thyroidectomy.
  • We defined the metastases as those cases in which serum thyroglobulin (Tg)increased significantly or in which we were able to prove the lesions on CT (computed tomography), MRI (magnetic resonance imaging) or bone scintigram.
  • The sensitivity of the mediastinum was appropriate, except for I-131 before ablation, and the sensitivity of the lung before and after ablation was inferior for either tracer.
  • [MeSH-minor] Adenocarcinoma, Follicular / diagnostic imaging. Adenocarcinoma, Follicular / secondary. Adenocarcinoma, Follicular / surgery. Adult. Aged. Cell Differentiation. Female. Humans. Iodine Radioisotopes. Male. Middle Aged. Postoperative Care. Radionuclide Imaging. Radiopharmaceuticals. Sensitivity and Specificity. Technetium Tc 99m Sestamibi. Thallium Radioisotopes

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16049563.001).
  • [ISSN] 0386-300X
  • [Journal-full-title] Acta medica Okayama
  • [ISO-abbreviation] Acta Med. Okayama
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Radiopharmaceuticals; 0 / Thallium Radioisotopes; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


77. Masutani K, Fujisaki K, Maeda H, Toyonaga J, Inoshima I, Takayama K, Katafuchi R, Hirakata H, Tsuruya K, Iida M: Tubulointerstitial nephritis and IgA nephropathy in a patient with advanced lung cancer treated with long-term gefitinib. Clin Exp Nephrol; 2008 Oct;12(5):398-402
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tubulointerstitial nephritis and IgA nephropathy in a patient with advanced lung cancer treated with long-term gefitinib.
  • Two years prior to admission, she was diagnosed with lung adenocarcinoma and multiple bone and brain metastases, and was treated with gefitinib (250 mg/day).
  • Treatment for 6 months induced partial response with 30% regression of the primary lung tumor, and resolution of metastatic tumors.
  • In consideration of the prognosis of lung cancer and complication of immunosuppressive treatment, we continued gefitinib only and closely followed-up the clinical course in the outpatient clinic.
  • However, the lung cancer started to increase in size.
  • [MeSH-major] Adenocarcinoma / drug therapy. Glomerulonephritis, IGA / chemically induced. Lung Neoplasms / drug therapy. Nephritis, Interstitial / chemically induced. Quinazolines / adverse effects. Quinazolines / therapeutic use

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2549-56 [16735708.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2240-50 [11980995.001]
  • [Cites] Arch Pathol Lab Med. 2005 Aug;129(8):1044-6 [16048398.001]
  • [Cites] Clin Exp Nephrol. 2005 Sep;9(3):262-3 [16189639.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):5054-9 [12941834.001]
  • [Cites] Lancet. 2003 Jan 11;361(9352):137-9 [12531582.001]
  • [Cites] Kidney Int. 2004 Nov;66(5):1805-14 [15496151.001]
  • [Cites] Am J Physiol. 1988 Dec;255(6 Pt 2):F1191-6 [3264462.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2504-5 [15197213.001]
  • [Cites] Clin Exp Nephrol. 2004 Dec;8(4):297-303 [15619027.001]
  • [Cites] FASEB J. 2004 May;18(7):926-8 [15033924.001]
  • [Cites] Nihon Kokyuki Gakkai Zasshi. 2003 Aug;41(8):565-8 [14503345.001]
  • [Cites] Kidney Int. 2003 Nov;64(5):1573-9 [14531789.001]
  • [Cites] J Biol Chem. 1999 Jun 18;274(25):17612-8 [10364198.001]
  • (PMID = 18575950.001).
  • [ISSN] 1342-1751
  • [Journal-full-title] Clinical and experimental nephrology
  • [ISO-abbreviation] Clin. Exp. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


78. Zhao C, Sun H, Yang Y, Dai X: [Pemetrexed combined DDP in the treatment of advanced non-small cell lung cancer: a case report and literature review]. Zhongguo Fei Ai Za Zhi; 2010 Jul;13(7):755-8
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pemetrexed combined DDP in the treatment of advanced non-small cell lung cancer: a case report and literature review].
  • BACKGROUND AND OBJECTIVE: The aim of this study is to integrate with literature review, and explore the value of treatment of advanced non-small cell lung cancer with second line.
  • METHODS: For the metastatic progressive non-small cell lung adenocarcinoma patient, the evaluation of efficacy for complete response (CR) with endostar combined GC, the sequential treatment with gefitinib, used pemetrexed combined DDP as the second line treatment, followed up and observed with the progression free survival (PFS) and survival time of patient.
  • RESULTS: Pemetrexed combined DDP in the treatment of 5 cycles, the evaluation of lung cancer efficacy for CR, bone metastasis was steady, PFS was 6.6 months, survival time is 22 months now, improved the quality of living life.
  • CONCLUSIONS: For advanced non-small cell lung adenocarcinoma recurrence and metastasis, after the treatment of first line and maintenance therapy, selecting adequately pemetrexed combined DDP, as the second line treatment, can prolong the lifetime and improve the quality of life.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20673495.001).
  • [ISSN] 1999-6187
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


79. Efstathiou E, Bozas G, Kostakopoulos A, Kastritis E, Deliveliotis C, Antoniou N, Skarlos D, Papadimitriou C, Dimopoulos MA, Bamias A: Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment. Urology; 2005 Jan;65(1):126-30
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
  • Patients with bone metastases also received zoledronic acid.
  • [MeSH-major] Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / secondary. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Alopecia / chemically induced. Androgen Antagonists / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Biomarkers, Tumor / blood. Combined Modality Therapy. Diphosphonates / administration & dosage. Disease Progression. Disease-Free Survival. Drug Resistance, Neoplasm. Estramustine / administration & dosage. Estramustine / adverse effects. Humans. Imidazoles / administration & dosage. Life Tables. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Proteins / blood. Neutropenia / chemically induced. Orchiectomy. Pain / drug therapy. Palliative Care. Prostate-Specific Antigen / blood. Radiotherapy, High-Energy. Remission Induction. Survival Analysis. Taxoids / administration & dosage. Taxoids / adverse effects. Treatment Outcome

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15667877.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0 / Diphosphonates; 0 / Imidazoles; 0 / Neoplasm Proteins; 0 / Taxoids; 15H5577CQD / docetaxel; 35LT29625A / Estramustine; 6XC1PAD3KF / zoledronic acid; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


80. Inaoka T, Takahashi K, Aburano T, Miyokawa N, Tandai S, Kobayashi T, Matsuno T: Spinal metastasis from lung cancer fifteen years after surgery presenting a pseudohemangioma appearance of the vertebra: a case report. Spine (Phila Pa 1976); 2010 Feb 1;35(3):E86-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal metastasis from lung cancer fifteen years after surgery presenting a pseudohemangioma appearance of the vertebra: a case report.
  • OBJECTIVE: To describe a case of solitary metastasis of the seventh thoracic vertebra (T7) from lung cancer 15 years after surgery.
  • SUMMARY OF BACKGROUND DATA: Late recurrence of the bone over 5 years after curative surgery for lung cancer is highly exceptional.
  • In addition, bone metastasis from lung cancer showing a coarse trabecular pattern of the vertebra on computed tomography (CT) is quite unusual.
  • METHODS: A case of solitary metastasis of T7 from lung cancer 15 years after surgery showing a pseudohemangioma appearance of the vertebra on CT is presented.
  • He had undergone a left lower lobectomy for lung cancer 15 years previously.
  • No other lesion was detected by whole-body CT and bone scintigraphy.
  • Tumor resection and T5-T9 posterior spinal fusion had been performed, and a pathologic diagnosis of metastatic pulmonary adenocarcinoma of the bone was established.
  • CONCLUSION: We have reported a rare case of solitary metastasis to T7 appearing 15 years after surgery for lung cancer.
  • The incidence of lung cancer recurrence more than 5 years after surgery is exceedingly low; however, even in patients with lung cancer, late occurrence of bone metastasis should be considered and included in the differential diagnosis of a pseudohemangioma appearance of the vertebra.
  • [MeSH-major] Hemangioma / radiography. Lung Neoplasms / radiography. Spinal Neoplasms / radiography. Spinal Neoplasms / secondary. Thoracic Vertebrae / radiography
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Male. Time Factors

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20075786.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. William WN Jr, Khuri FR, Fossella FV, Glisson BS, Zinner RG, Lee JJ, Herbst RS, Lippman SM, Kim ES: Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small-cell lung cancer as frontline and second-line therapy. Am J Clin Oncol; 2010 Apr;33(2):148-52
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small-cell lung cancer as frontline and second-line therapy.
  • OBJECTIVES: Combination chemotherapy with third-generation, nonplatinum agents (ie, gemcitabine, vinorelbine, taxanes, or camptothecins) represents a well-tolerated frontline treatment option for metastatic non-small-cell lung cancer and might play a role as salvage therapy as well.
  • The aim of this phase 2 study was to investigate the use of docetaxel and vinorelbine in the frontline and second-line setting in patients with incurable non-small-cell lung cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Squamous Cell / drug therapy. Lung Neoplasms / drug therapy. Salvage Therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19687727.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; 5V9KLZ54CY / Vinblastine; Q6C979R91Y / vinorelbine
  •  go-up   go-down


82. Rossi D, Dennetta D, Ugolini M, Alessandroni P, Catalano V, Fedeli SL, Giordani P, Casadei V, Baldelli AM, Graziano F, Catalano G: Weekly paclitaxel in elderly patients (aged &gt; or = 70 years) with advanced non-small-cell lung cancer: an alternative choice? Results of a phase II study. Clin Lung Cancer; 2008 Sep;9(5):280-4
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Weekly paclitaxel in elderly patients (aged > or = 70 years) with advanced non-small-cell lung cancer: an alternative choice? Results of a phase II study.
  • PURPOSE: Paclitaxel and platinum-based chemotherapy is considered to be a standard approach for locally advanced and metastatic non-small-cell lung cancer (NSCLC).
  • The aim of our study was to investigate the activity and safety of weekly paclitaxel in elderly patients with locally advanced (stage IIIB) and metastatic (stage IV) NSCLC.
  • CONCLUSION: Our study confirmed that paclitaxel 80 mg/m2 weekly is active in patients with locally advanced and metastatic NSCLC with a good safety profile; this schedule might be considered an alternative choice to gemcitabine or vinorelbine as first-line treatment in elderly patients, particularly patients with comorbidities.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Paclitaxel / therapeutic use
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Aged. Aged, 80 and over. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Carcinoma / drug therapy. Carcinoma / secondary. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Female. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Male. Prognosis. Salvage Therapy. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18824450.001).
  • [ISSN] 1525-7304
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


83. Nannuru KC, Futakuchi M, Varney ML, Vincent TM, Marcusson EG, Singh RK: Matrix metalloproteinase (MMP)-13 regulates mammary tumor-induced osteolysis by activating MMP9 and transforming growth factor-beta signaling at the tumor-bone interface. Cancer Res; 2010 May 1;70(9):3494-504
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Matrix metalloproteinase (MMP)-13 regulates mammary tumor-induced osteolysis by activating MMP9 and transforming growth factor-beta signaling at the tumor-bone interface.
  • The tropism of breast cancer cells for bone and their tendency to induce an osteolytic phenotype are a result of interactions between breast cancer cells and stromal cells and are of paramount importance for bone metastasis.
  • We hypothesize that tumor-stromal interaction alters gene expression in malignant tumor cells and stromal cells creating a unique expression signature that promotes osteolytic breast cancer bone metastasis and that inhibition of such interactions can be developed as targeted therapeutics.
  • Microarray analysis was performed to investigate gene expression profiling at the tumor-bone (TB) interface versus the tumor alone area from syngenic mice injected with three different syngenic mammary tumor cell lines that differ in their metastatic potential.
  • Knockdown of MMP13 expression at the TB interface leads to significant reduction in bone destruction and in the number of activated osteoclasts at the TB interface.
  • Further analysis to evaluate the mechanism of MMP13-dependent osteolytic bone metastasis revealed that MMP13-ASO treatment decreased active MMP9, RANKL levels, and transforming growth factor-beta signaling at the TB interface.
  • Together, our data indicate that upregulation of MMP13 at the TB interface is important in tumor-induced osteolysis and suggest that MMP13 is a potential therapeutic target for breast cancer bone metastasis.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c)2010 AACR.
  • [Cites] Am J Pathol. 1999 Feb;154(2):469-80 [10027405.001]
  • [Cites] Clin Exp Metastasis. 2009;26(7):797-808 [19590968.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Mar 18;328(3):679-87 [15694401.001]
  • [Cites] Int J Cancer. 2005 Apr 20;114(4):544-54 [15551360.001]
  • [Cites] Cancer Cell. 2005 May;7(5):485-96 [15894268.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Jan;3(1):41-9 [16407878.001]
  • [Cites] Nature. 2006 Apr 27;440(7088):1222-6 [16642001.001]
  • [Cites] Lung Cancer. 2006 Jun;52(3):349-57 [16569461.001]
  • [Cites] Cancer Metastasis Rev. 2006 Dec;25(4):541-9 [17180711.001]
  • [Cites] Cancer Res. 2008 Jul 15;68(14):5803-11 [18632634.001]
  • [Cites] Cancer Sci. 2009 Jan;100(1):71-81 [19038005.001]
  • [Cites] Clin Exp Metastasis. 2009;26(3):205-13 [19112599.001]
  • [Cites] Cancer Lett. 2009 Apr 18;276(2):212-20 [19114293.001]
  • [Cites] J Clin Invest. 2009 Apr;119(4):837-51 [19307728.001]
  • [Cites] Clin Cancer Res. 2009 May 1;15(9):3143-9 [19383809.001]
  • [Cites] PLoS One. 2009;4(5):e5620 [19440335.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Mol Cancer Res. 2009 Aug;7(8):1224-33 [19671689.001]
  • [Cites] Genes Dev. 2000 Jan 15;14(2):163-76 [10652271.001]
  • [Cites] Biochim Biophys Acta. 1999 Dec 10;1489(1):19-30 [10806994.001]
  • [Cites] Adv Immunol. 2000;75:115-57 [10879283.001]
  • [Cites] J Cell Biol. 2000 Nov 13;151(4):879-89 [11076971.001]
  • [Cites] Surg Oncol Clin N Am. 2001 Apr;10(2):383-92, x [11382593.001]
  • [Cites] Curr Opin Investig Drugs. 2001 Oct;2(10):1444-9 [11890363.001]
  • [Cites] Int J Oncol. 2002 Jul;21(1):25-30 [12063545.001]
  • [Cites] Crit Rev Biochem Mol Biol. 2002;37(3):149-66 [12139441.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):584-93 [12154351.001]
  • [Cites] Br J Cancer. 2003 Apr 22;88(8):1318-26 [12698202.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1655-64 [15084698.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):3110-6 [15131051.001]
  • [Cites] Methods Enzymol. 1987;144:140-71 [3041177.001]
  • [Cites] Cancer Res. 1991 Jun 1;51(11):3059-61 [2032246.001]
  • [Cites] Cancer Res. 1992 Mar 15;52(6):1399-405 [1540948.001]
  • [Cites] J Cell Biochem. 1993 Dec;53(4):288-95 [8300745.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2823-6 [8187059.001]
  • [Cites] Annu Rev Biochem. 1998;67:753-91 [9759503.001]
  • [Cites] J Pathol. 1998 Oct;186(2):144-50 [9924429.001]
  • [Cites] J Biol Chem. 1994 Jun 17;269(24):16766-73 [8207000.001]
  • [Cites] Int J Cancer. 1996 Aug 22;69(4):350-3 [8797881.001]
  • [Cites] J Clin Invest. 1996 Oct 1;98(7):1544-9 [8833902.001]
  • [Cites] J Bone Miner Res. 1996 May;11(5):665-70 [9157781.001]
  • [Cites] Am J Pathol. 1997 Aug;151(2):499-508 [9250162.001]
  • [Cites] EMBO J. 1997 Sep 1;16(17):5353-62 [9311995.001]
  • [Cites] Eur J Biochem. 1997 Sep 1;248(2):369-73 [9346290.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4882-8 [9354453.001]
  • [Cites] Cancer. 1997 Oct 15;80(8 Suppl):1546-56 [9362421.001]
  • [Cites] Cancer. 1997 Oct 15;80(8 Suppl):1588-94 [9362426.001]
  • [Cites] Cancer Res. 1998 Apr 1;58(7):1348-52 [9537227.001]
  • [Cites] Am J Pathol. 1998 Jul;153(1):91-101 [9665469.001]
  • [Cites] Endocr Relat Cancer. 1999 Sep;6(3):333-47 [10516850.001]
  • (PMID = 20406980.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA72781; United States / NCI NIH HHS / CA / R29 CA072781; United States / PHS HHS / / KG090860; United States / NCI NIH HHS / CA / CA072781-08; United States / NCI NIH HHS / CA / R01 CA072781-08; United States / NCI NIH HHS / CA / P30 CA036727; United States / NCI NIH HHS / BC / BC083293; None / None / / P30 CA036727-24; United States / NCI NIH HHS / CA / R01 CA072781; United States / NCI NIH HHS / CA / P30 CA036727-24; United States / NCI NIH HHS / CA / P30CA036727
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Matrix Metalloproteinase Inhibitors; 0 / Osteoprotegerin; 0 / RANK Ligand; 0 / RNA, Messenger; 0 / Tnfrsf11b protein, mouse; 0 / Tnfsf11 protein, mouse; 0 / Transforming Growth Factor beta; EC 3.4.24.- / Matrix Metalloproteinase 13; EC 3.4.24.35 / Matrix Metalloproteinase 9
  • [Other-IDs] NLM/ NIHMS186360; NLM/ PMC2862120
  •  go-up   go-down


84. Huang H, Zhang Y, Zhao HY, Wang ZQ, Xu F, Xu GC, Zhang L, Guan ZZ: [Analysis of the efficacy and safety of gefitinib in the treatment of recurrent advanced non-small cell lung cancer in an expanded access program (EAP)]. Zhonghua Zhong Liu Za Zhi; 2009 Feb;31(2):148-51
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of the efficacy and safety of gefitinib in the treatment of recurrent advanced non-small cell lung cancer in an expanded access program (EAP)].
  • OBJECTIVE: The aim of this study is to evaluate the efficacy and safety of Gefitinib in the treatment of Chinese patients with recurrent advanced non-small-cell lung cancer (NSCLC).
  • All patients were histologically or/and cytologically confirmed to have a locally advanced or metastatic NSCLC, and failed to previous standard treatments.
  • The results of COX model analysis suggested that the patients with adenocarcinoma, rash and favourable performance status (PS) had longer TTP.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Diarrhea / chemically induced. Exanthema / chemically induced. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Proportional Hazards Models. Remission Induction. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19538895.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


85. Bahk WJ, Rhee SK, Kang YK, Lee AH, Park JM, Chung YG: Gastric cancer acrometastases to all digits of one hand following closed intramedullary nailing. Skeletal Radiol; 2006 Jul;35(7):529-32
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metastatic malignant tumor of the hand is unusual and the most common site of the primary cancer is lung.
  • Acrometastases to the phalanges of the hand usually involve a single bone, while those proximal to the phalanges often involve multiple bones.
  • To our knowledge, only five cases have been reported in the literature to date and there has been no reported case following closed intramedullary nailing for metastatic diaphyseal fracture of an ipsilateral long bone.
  • [MeSH-major] Adenocarcinoma / complications. Bone Neoplasms / complications. Fingers / pathology. Fracture Fixation, Intramedullary. Fractures, Spontaneous / etiology. Humerus / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Exp Metastasis. 1983 Jul-Sep;1(3):205-12 [6546199.001]
  • [Cites] J Hand Surg Br. 1988 Aug;13(3):306-7 [3171299.001]
  • [Cites] Hand Surg. 2001 Dec;6(2):239-42 [11901474.001]
  • [Cites] J Bone Joint Surg Am. 1996 Jun;78(6):891-6 [8666607.001]
  • [Cites] Surgery. 1951 Mar;29(3):466-72 [14835133.001]
  • [Cites] Acta Cytol. 1994 Jul-Aug;38(4):589-91 [8042428.001]
  • [Cites] Hand. 1972 Oct;4(3):268-72 [5083969.001]
  • [Cites] J Bone Joint Surg Am. 1972 Dec;54(8):1665-76 [4569465.001]
  • [Cites] J Bone Joint Surg Am. 1976 Dec;58(8):1061-6 [1002745.001]
  • [Cites] J Surg Oncol. 1983 Oct;24(2):99-102 [6632902.001]
  • [Cites] J Bone Joint Surg Am. 1983 Dec;65(9):1331-5 [6654944.001]
  • [Cites] J Bone Joint Surg Am. 1986 Jun;68(5):743-6 [3459730.001]
  • [Cites] Br J Cancer. 1965 Mar;19:15-29 [14284378.001]
  • [Cites] Arch Surg. 1967 Mar;94(3):307-12 [6018878.001]
  • [Cites] Cancer. 1970 Dec;26(6):1199-203 [5483651.001]
  • [Cites] J Hand Surg Am. 1978 May;3(3):271-6 [275346.001]
  • [Cites] J Surg Oncol. 1985 Feb;28(2):146-50 [2982063.001]
  • (PMID = 16283175.001).
  • [ISSN] 0364-2348
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


86. Kosmas C, Tsavaris N, Syrigos K, Koutras A, Tsakonas G, Makatsoris T, Mylonakis N, Karabelis A, Stathopoulos GP, Kalofonos HP: A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens. Cancer Chemother Pharmacol; 2007 Jan;59(1):51-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens.
  • PURPOSE: Treatment options in patients with recurrent non-small cell lung cancer (NSCLC) remain limited as a result of poor activity of most agents after failure of platinum-based therapy.
  • RESULTS: Forty-nine patients entered the phase I and II part of the study (phase I: 12-phase II: 37 + 3 at DL-3), and 40 patients were evaluable for a response in phase II and all for toxicity: median age, 61 years (range 36-74); PS, 1 (0-2); gender, 43 males/6 females-histologies; adenocarcinoma, 25; squamous, 20; large cell, 4.
  • Metastatic sites included lymph nodes, 38; bone, 5; liver, 4; brain, 3; lung nodules, 14; adrenals, 13; other, 3.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16622691.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Bridged Compounds; 0 / Organoplatinum Compounds; 0 / Taxoids; 0W860991D6 / Deoxycytidine; 1605-68-1 / taxane; 7673326042 / irinotecan; B76N6SBZ8R / gemcitabine; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


87. Kulig J, Matyja A, Kowalewski M, Kratochwil M: [Abstract: case report of isolated metastasis to the spleen in a patient operated due to cancer of the sigmoid colon]. Folia Med Cracov; 2009;50(3-4):71-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Isolated metastatic tumor of the spleen is rare and usually encompass the presence of neoplasmatic dissemination.
  • The most frequent location of metastasis is right lobe of the liver, however solitaire secondary tumor to distant organ such as brain, lung, bone marrow or other might be discovered.
  • Splenectomy is a method of choice therefore may be justified in presence of isolated metastatic disease, because of low complication rate, providing potential long-term survival.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Sigmoid Neoplasms / pathology. Sigmoid Neoplasms / surgery. Splenic Neoplasms / secondary. Splenic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21853873.001).
  • [ISSN] 0015-5616
  • [Journal-full-title] Folia medica Cracoviensia
  • [ISO-abbreviation] Folia Med Cracov
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


88. Tamiolakis D, Tsamis I, Thomaidis V, Lambropoulou M, Alexiadis G, Venizelos I, Jivanakis T, Papadopoulos N: Oral complaints caused from metastases to the mandible and maxilla. Chirurgia (Bucur); 2007 Jul-Aug;102(4):439-42

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Jaw bone disorders causing oral complaints are common in primary care settings.
  • However they also may be the symptoms of a primary or secondary malignant process in the bone.
  • The most common malignant bone tumor is metastatic carcinoma, and tumors arising in the breast, prostate, thyroid, lung and kidney have a special propensity to spread to bone.
  • We describe four cases of metastatic tumours to the jaws.
  • Physicians who frequently advise patients with oral complaints should keep in mind that whereas these symptoms are mostly of a chronic and benign nature, metastases from a malignant tumor must be included in the differential diagnosis.
  • [MeSH-major] Adenocarcinoma / secondary. Facial Pain / etiology. Mandibular Neoplasms / secondary. Maxillary Neoplasms / secondary
  • [MeSH-minor] Aged. Diagnosis, Differential. Esophageal Neoplasms / pathology. Female. Humans. Liver Neoplasms / pathology. Male. Medical Records. Middle Aged. Retrospective Studies. Survival Rate. Thyroid Neoplasms / pathology. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17966942.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


89. Blesa JM, Pulido EG: Colorectal cancer: response to sunitinib in a heavily pretreated colorectal cancer patient. Anticancer Drugs; 2010 Jan;21 Suppl 1:S23-6
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient was diagnosed with a rectum-sigma adenocarcinoma (pT1N0M0 stage).
  • Due to the development of subsequent recurrences (infravesical relapse, bone and lung progression) associated with CEA progression and pain worsening, the patient received treatment by every available agent for the metastatic colorectal cancer, including oxaliplatin and radiotherapy; irinotecan; FOLFOX schema; oral capecitabine; raltitrexed; irinotecan and cetuximab; cetuximab as a single agent; always in combination with zolendronic acid-based treatment for pain control.
  • On account of the nonmeasurable disease nature of the metastatic presentation in the present case, the clinical benefit was measured in terms of reduction of painkiller intake, improvement in performance status of the patient, and CEA serum levels.
  • In addition to all of these clinical and biological data, CT images showed an increase in necrotic area of the bone lesion without any decrease in tumor size by classical RECIST criteria.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Colorectal Neoplasms / drug therapy. Indoles / therapeutic use. Pyrroles / therapeutic use

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20110784.001).
  • [ISSN] 1473-5741
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Carcinoembryonic Antigen; 0 / Indoles; 0 / Pyrroles; 0 / sunitinib
  •  go-up   go-down


90. Eroglu A, Karaoglanoglu N, Bilen H, Gursan N: Follicular thyroid carcinoma: metastasis to the sternum, 13 years after total thyroidectomy. Int J Clin Pract; 2006 Nov;60(11):1506-8
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary and metastatic malignancies of the sternum are uncommon.
  • Secondary lesions to the sternum occur more commonly in patients with lung and breast cancer, and only a few cases of sternal metastasis arising from a follicular thyroid carcinoma have been reported in the literature.
  • Rarely, metastases to the sternum present in the guise of primary sternal tumours may be treated surgically with that diagnosis in mind.
  • Late metastatic thyroid carcinoma to the sternum should be kept in mind in the differential diagnosis of sternal lesions.
  • [MeSH-major] Adenocarcinoma, Follicular / secondary. Bone Neoplasms / secondary. Sternum. Thyroid Neoplasms

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Clin Pract. 2007 Mar;61(3):521; author reply 521-2 [17313627.001]
  • (PMID = 17073845.001).
  • [ISSN] 1368-5031
  • [Journal-full-title] International journal of clinical practice
  • [ISO-abbreviation] Int. J. Clin. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


91. Pentheroudakis G, Golfinopoulos V, Pavlidis N: Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur J Cancer; 2007 Sep;43(14):2026-36
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Published reports on identification of CUP primary site by autopsy or microarray-based multigene expression platforms were retrieved and analysed for year of publication, primary site, patient age, gender, histology, rate of primary identification, manifestations and metastatic deposits, microarray chip technology, training and validation sets, mathematical modelling, classification accuracy and number of classifying genes.
  • RESULTS: From 1944 to 2000, a total of 884 CUP patients (66% males) underwent autopsy in 12 studies after presenting with metastatic or systemic symptoms and succumbing to their disease.
  • A primary was identified in 644 (73%) of them, mostly in the lung (27%), pancreas (24%), hepatobiliary tree (8%), kidneys (8%), bowel, genital system and stomach, as a small focus of adenocarcinoma or poorly differentiated carcinoma.
  • An unpredictable systemic dissemination was evident with high frequency of lung (46%), nodal (35%), bone (17%), brain (16%) and uncommon (18%) deposits.
  • Between the 1944-1980 and the 1980-2000 series, female representation increased, 'undetermined neoplasm' diagnosis became rarer, pancreatic primaries were found less often while colonic ones were identified more frequently.
  • Four studies using microarray technology profiled more than 500 CUP cases using classifier set of genes (ranging from 10 to 495) and reported strikingly dissimilar frequencies of assigned primary sites (lung 11.5%, pancreas 12.5%, bowel 12%, breast 15%, hepatobiliary tree 8%, kidneys 6%, genital system 9%, bladder 5%) in 75-90% of the cases.
  • Discrepant assignment of primary sites by microarrays may be due to the presence of 'sanctuary sites' in autopsies, molecular misclassification and the postulated presence of a pro-metastatic genetic signature.
  • [MeSH-major] Microarray Analysis / methods. Neoplasms, Unknown Primary / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17698346.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


92. Tamura M, Dohhba S, Funaki K, Sasaki S, Michiwa Y, Kurosaka Y, Takekawa S, Kiriyama M, Kojima Y, Kita T: [Pulmonary pleomorphic carcinoma; report of 2 cases]. Kyobu Geka; 2006 Jul;59(7):585-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Biopsy of the bone revealed metastatic adenocarcinoma.
  • With a diagnosis of primary lung cancer (cT2N1M1), two-staged operation was performed.
  • Pathological diagnosis was pleomorphic carcinoma [pT2N1M1 (OSS), stage IV].
  • Chest CT revealed a tumor in the right hilar region, which was diagnosed as adenocarcinoma by transbronchial lung biopsy.
  • Autopsy revealed pleomorphic carcinoma of the lung with metastasis to the brain, costa and mediastinal lymph nodes.
  • [MeSH-major] Adenocarcinoma / radiography. Carcinoma / radiography. Lung Neoplasms / radiography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16856536.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


93. Thöm I, Schult-Kronefeld O, Burkholder I, Schuch G, Andritzky B, Kastendieck H, Edler L, Wagener C, Bokemeyer C, Schumacher U, Laack E: Expression of CEACAM-1 in pulmonary adenocarcinomas and their metastases. Anticancer Res; 2009 Jan;29(1):249-54
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In contrast, CEACAM-1 is not expressed in normal lung tissue or melanocytes.
  • It has been demonstrated that an expression in these tissues is associated with the development of metastatic disease.
  • The aim of the present investigation was to analyze a possible association between the expression of CEACAM-1 in pulmonary adenocarcinomas and their lymph node and hematogenous metastatic cells.
  • PATIENTS AND METHODS: CEACAM-1 expression was immunhistochemically evaluated in primary tumors, lymph nodes and distant metastases of 96 patients with metastatic pulmonary adenocarcinoma who had undergone surgery between 1999 and 2002.
  • This investigation demonstrates that its expression is preserved in lymph node and hematogenous metastases, indicating that its expression is of functional significance for both metastatic sites.
  • These results support the prognostic relevance of the expression of CEACAM-1 in pulmonary adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / immunology. Adenocarcinoma / secondary. Antigens, CD / biosynthesis. Cell Adhesion Molecules / biosynthesis. Lung Neoplasms / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19331157.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD66 antigens; 0 / Cell Adhesion Molecules
  •  go-up   go-down


94. Vitagliano D, Portella G, Troncone G, Francione A, Rossi C, Bruno A, Giorgini A, Coluzzi S, Nappi TC, Rothstein JL, Pasquinelli R, Chiappetta G, Terracciano D, Macchia V, Melillo RM, Fusco A, Santoro M: Thyroid targeting of the N-ras(Gln61Lys) oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomas. Oncogene; 2006 Aug 31;25(39):5467-74
SciCrunch. Marmoset Gene list: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • About 25% of the Tg-N-ras carcinomas displayed large, poorly differentiated areas, featuring vascular invasion and forming lung, bone or liver distant metastases.
  • These findings support the notion that mutated ras oncogenes could be able to drive the formation of thyroid tumors that can progress to poorly differentiated, metastatic carcinomas.
  • [MeSH-minor] Adenocarcinoma, Follicular / genetics. Adenocarcinoma, Follicular / pathology. Adenoma / genetics. Adenoma / pathology. Amino Acid Substitution. Animals. Cell Differentiation. Humans. Mice. Mice, Transgenic. Neoplasm Invasiveness


95. Yoneyama K, Yamada A, Koshida Y, Toriumi F, Murayama T, Toeda H, Imazu Y, Motegi K, Akamatsu H, Ooyama R: [A patient with pulmonary metastasis from breast cancer after surgery who responded to S-1]. Gan To Kagaku Ryoho; 2007 Jul;34(7):1143-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thoracic CT at the end of the sixth course revealed the disappearance of the metastatic focus.
  • S-1 showed potent antitumor effects and good tolerance, and it may be useful for treating metastatic/recurrent breast cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Antimetabolites, Antineoplastic / therapeutic use. Breast Neoplasms / surgery. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Oxonic Acid / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Antigens, Tumor-Associated, Carbohydrate / blood. Biomarkers, Tumor / blood. Bone Neoplasms / radiotherapy. Bone Neoplasms / secondary. Carcinoembryonic Antigen / blood. Chemotherapy, Adjuvant. Combined Modality Therapy. Drug Administration Schedule. Drug Combinations. Female. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Mastectomy, Segmental. Middle Aged. Mucin-1 / blood. Quality of Life

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17637559.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Antimetabolites, Antineoplastic; 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Drug Combinations; 0 / Mucin-1; 0 / ST 439 antigen, human; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


96. Currall VA, Dixon JH: Synovial metastasis: an unusual cause of pain after total knee arthroplasty. J Arthroplasty; 2008 Jun;23(4):631-6
MedlinePlus Health Information. consumer health - Knee Replacement.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Synovial biopsy revealed metastatic adenocarcinoma of colorectal type.
  • The knee is the most frequently affected joint, and the lung is the most common primary site for synovial metastasis.
  • This phenomenon should be considered in the differential diagnosis of continuing pain and effusion postarthroplasty.
  • [MeSH-major] Adenocarcinoma / secondary. Arthroplasty, Replacement, Knee. Bone Neoplasms / secondary. Colorectal Neoplasms / diagnosis. Joint Diseases / diagnosis. Knee Joint. Pain, Postoperative / etiology. Synovial Membrane
  • [MeSH-minor] Aged. Arthroscopy. Biopsy. Diagnosis, Differential. Humans. Male. Neoplasm Recurrence, Local / pathology. Osteoarthritis, Knee / surgery

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Joint Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18514889.001).
  • [ISSN] 0883-5403
  • [Journal-full-title] The Journal of arthroplasty
  • [ISO-abbreviation] J Arthroplasty
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Pillai P, Mendel E, Ray-Chaudhury A, Slone W, Ammirati M, Chiocca AE: Metastasis development at the site of cervical spine arthrodesis. Acta Neurochir (Wien); 2010 Mar;152(3):509-13
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Biologically, the site of arthrodesis provides a microenvironment replete of growth factors and active remodeling, which is propitious for bone regrowth.
  • There is a theoretical possibility though that this microenvironment would also provide a fertile site for metastatic deposits to occur.
  • We present the clinical, radiographic, and pathological features of a case of previously undiagnosed metastatic adenocarcinoma, occurring 1 year following anterior arthrodesis and fusion for cervical spondylotic myelopathy at the C3-C4 level.
  • [MeSH-major] Adenocarcinoma / secondary. Arthrodesis / adverse effects. Lung Neoplasms / pathology. Spinal Fusion / adverse effects. Spinal Neoplasms / secondary. Spondylosis / surgery
  • [MeSH-minor] Bone Regeneration / physiology. Cervical Vertebrae / pathology. Cervical Vertebrae / radiography. Cervical Vertebrae / surgery. Chemotaxis / physiology. Decompression, Surgical. Disease Progression. Diskectomy / adverse effects. Fatal Outcome. Humans. Intercellular Signaling Peptides and Proteins / metabolism. Intercellular Signaling Peptides and Proteins / secretion. Intervertebral Disc Displacement / pathology. Intervertebral Disc Displacement / radiography. Intervertebral Disc Displacement / surgery. Male. Middle Aged. Neoplasm Metastasis / pathology. Neoplasm Metastasis / physiopathology. Neoplasm Metastasis / prevention & control. Neurosurgical Procedures. Osteogenesis / physiology. Reoperation. Spinal Cord Compression / pathology. Spinal Cord Compression / radiography. Spinal Cord Compression / surgery. Spinal Stenosis / pathology. Spinal Stenosis / radiography. Spinal Stenosis / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19551339.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Intercellular Signaling Peptides and Proteins
  •  go-up   go-down


98. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De Vathaire F, Schlumberger M: Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab; 2006 Aug;91(8):2892-9
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A total of 444 patients were treated from 1953-1994 for distant metastases from papillary and follicular thyroid carcinoma: 223 had lung metastases only, 115 had bone metastases only, 82 had both lung and bone metastases, and 24 had metastases at other sites.
  • Treatment consisted of the administration of 3.7 GBq (100 mCi) (131)I after withdrawal of thyroid hormone treatment, every 3-9 months during the first 2 yr and then once a year until the disappearance of any metastatic uptake.
  • [MeSH-major] Adenocarcinoma, Follicular / radiotherapy. Carcinoma, Papillary / radiotherapy. Iodine Radioisotopes / therapeutic use. Neoplasm Metastasis / radiotherapy. Thyroid Neoplasms / radiotherapy. Treatment Outcome
  • [MeSH-minor] Adolescent. Adult. Aged. Bone Neoplasms / radiotherapy. Bone Neoplasms / secondary. Child. Child, Preschool. Female. Humans. Lung Neoplasms / radiotherapy. Lung Neoplasms / secondary. Male. Middle Aged. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Clin Pract Endocrinol Metab. 2006 Nov;2(11):610-1 [17082807.001]
  • (PMID = 16684830.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


99. David A, Blotta A, Rossi R, Zatelli MC, Bondanelli M, Roti E, Braverman LE, Busutti L, degli Uberti EC: Clinical value of different responses of serum thyroglobulin to recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma. Thyroid; 2005 Mar;15(3):267-73
Hazardous Substances Data Bank. THYROGLOBULIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twenty-seven patients had high positive rhTSH Tg testing and (131)I uptake was detected in lung, bone, or mediastinum in 11.
  • Imaging techniques (computed tomography [CT], magnetic resonance imaging [MRI], fluorine-18 2-fluoro-2-deoxy-D-glucose-positron emission tomography [FDGPET]) documented metastatic disease in 22.
  • [MeSH-minor] Adenocarcinoma, Papillary / blood. Adenocarcinoma, Papillary / pathology. Adolescent. Adult. Aged. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Positron-Emission Tomography. Recurrence. Reproducibility of Results. Thyroidectomy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15785246.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Proteins; 9002-71-5 / Thyrotropin; 9010-34-8 / Thyroglobulin
  •  go-up   go-down


100. Yamamoto N, Kinoshita H, Inoue T, Kawakita S, Oguchi N, Muguruma K, Kawa G, Sakaguchi Y, Adachi Y, Sakaida N, Uemura Y, Matsuda T: [Small cell carcinoma of the prostate: a case report]. Hinyokika Kiyo; 2007 Sep;53(9):665-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 76-year-old man had been treated with maximum androgen blockade therapy for a poorly-differentiated prostate adenocarcinoma (T3cN1M0, prostate specific antigen (PSA) 65 ng/ml, Gleason Score 4+5=9) since September 2002.
  • At that time, no metastasis was detected by computed tomography and bone scintigraphy.
  • In August 2005, multiple bone metastases were detected.
  • Immunohistochemical examination of a biopsy specimen from the bone lesion revealed a small cell carcinoma/neuroendocrine cell carcinoma.
  • The autopsy showed multiple organ metastases including bone, liver, lungs and others.
  • The immunohistochemical examination revealed pure small cell carcinoma in all metastatic lesions.
  • A precise histological examination of the lungs using a 1 cm serial section could not reveal any tumors compatible with primary lung cancer.
  • We concluded from the clinical history and autopsy findings that his initial poorly-differentiated adenocarcinoma of the prostate dedifferentiated into a pure small cell carcinoma with neuroendocrine differentiation.
  • [MeSH-minor] Adenocarcinoma / pathology. Aged. Cell Transformation, Neoplastic. Humans. Male. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17933147.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 20
  •  go-up   go-down






Advertisement